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6/j.bRelapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation
(alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die
of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune
suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions
are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hema-
tologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies,
and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are
generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific
trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under inves-
tigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for
specific areas of research necessary in the treatment of relapse after alloHSCT.
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Relapsed disease is amajor cause of treatment failure
after allogeneic hematopoietic stem cell transplantation
(alloHSCT). Treatment options for patients who re-
lapse have been inadequate, and the majority of these
patients ultimately die of their disease. Although donor
lymphocyte/leukocyte infusions (DLIs) have been
dramatically effective for patients with relapsed chronic
myelogenous leukemia (CML), they have limited activ-
ity for patients who relapse with acute leukemia. The
role of graft-versus-leukemia (GVL), or more generi-
cally, graft-versus-tumor (GVT) induction with DLI is
less well defined for patients who relapse with diseases
other than CML and acute leukemia, but it is clear
that, at least in some cases, sustained remissions are in-
duced for patients with chronic lymphocytic leukemia
(CLL), multiple myeloma (MM), Hodgkin lymphoma
(HL), and non-Hodgkin lymphoma (NHL). Impor-
tantly, there is very limited information on therapeutic
interventions other than DLI to treat relapse after
alloHSCT.1467
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tions for patients who relapse after alloHSCT.There is
no standard approach for relapse of a specific disease
because treatment options are dependent on many fac-
tors including disease activity, timing of relapse, clini-
cal complications, graft-versus-host disease (GVHD),
the use of immunosuppression, prior therapies, donor
availability, susceptibility to GVT induction, alterna-
tive options, and many other issues. However, many
issues are relevant across all diseases. Timing, dose,
and scheduling of DLIs are not well defined except
for CML. Novel approaches to enhance GVT induc-
tion by either improving T cell function or specificity
are being studied for several diseases. Second trans-
plants remain a viable option for a small subset of pa-
tients who relapse, and there is a rapidly growing list
of biological therapies that have activity in relapse
when GVT induction is not appropriate or effective.
Understanding the biology of relapse [1] and defining
the role for currently available treatment options is crit-
ical to develop and rapidly test new and potentially
curative therapies for relapse after alloHSCT.CML
Summary of Current Status
Although alloHSCT was previously the therapy of
choice for patients with CML in chronic phase (CP),
the advent of tyrosine kinase inhibitors (TKIs) now
limits this approach topatients that are resistant to or in-
tolerant of these drugs. Patients suffering from
accelerated phase (AP) or blast crisis (BC) CML may
preferentially be transplanted after entering a second
CP of the disease following chemotherapy and/or
TKI therapy. Although the relapse rate after
alloHSCT is low forCPpatients, the relapse rate for pa-
tients transplanted in AP or BC is high, and treatment
requires a different strategy. The choice of treatment
of relapse after transplantation depends not only on
the disease state at the time of relapse, but is also influ-
enced by the initial treatment, because most patients
transplanted in CP are resistant to first generation
TKIs. Relapse after transplantation can be divided
into molecular relapse or persistence (as defined by
the detection by polymerase chain reaction (PCR) of
BCR/ABLmRNA transcripts in the absence of cytoge-
netic abnormalities), cytogenetic relapse, or hemato-
logic relapse of CP, AP, or BC.
CML is particularly sensitive to control by alloge-
neic donor T cells, the GVL effect. This was initially
demonstrated in patients who remitted when immuno-
suppression was stopped and GVHD flared, by the
observation of high relapse rates if the alloHSCT
utilized T cell-depleted allografts, and subsequently
confirmed by sensitivity of relapsed CML to DLI
[2-5]. At present, only limited data support theconcept of a disease-specific GVL reaction [6,7]. It is
likely that much of the effect reflects graft-versus-
hematopoiesis or a less specificGVHDreaction toward
minor histocompatibility antigens (mHag) such as
HA-1 or H-Y [8-10].
The majority of patients with CP CML who have
molecular, cytogenetic, or hematologic relapses enter
sustained remissions after treatment with DLIs. Com-
plete remission (CR) rates of 70% to 90% in CP CML
have been reported even with relatively low doses of
DLI. The interval between DLI and response appears
to be dependent on T cell dose. Similarly, the develop-
ment of GVHD after DLI is dependent on the T cell
dose and the interval between alloHSCT and DLI.
Higher doses of DLI and shorter interval between al-
loHSCT and DLI are associated with increased risk
of GVHD [11-13]. Because the progression rate of
relapsed CML CP is slow, DLIs may be started at
low doses of 0.3-1  107 CD31 cells/kg leading to
clinical response as late as 1 year following treatment
[14].
In contrast, CML in AP and BC are less susceptible
to treatment with DLI only. Although remission rates
of 20% to 40% [15] have been reported, because of the
aggressive character of the disease, control of the ma-
lignancy by additional pretreatment with chemother-
apy with or without TKIs may be necessary to allow
sufficient time and circumstances for a therapeutic im-
mune response to occur. Alternatively, patients may be
treated with combined DLIs and TKIs. However, the
role of TKIs in the successful treatment of patients
who have been previously resistant to TKIs (eg, with
T315I mutations) awaits the development of more
specific drugs.
Finally, there is a small cohort of patientswith extra-
medullary relapses. These may occur after the primary
transplant or may even occur after remission induction
with DLI. These relapses tend to be resistant to further
immunologic interventions [16,17].
Treatment Options for Relapsed CML after
alloHSCT
Withdrawal of immune suppression
Because CML is highly susceptible to T cell-
mediated recognition by donor T cells, tapering im-
mune suppression administered after transplantation
for prevention or treatment of GVHD may lead to
activation of alloreactive T cells capable of suppressing
or eradicating the malignancy [18]. Discontinuation of
immune suppression may also be necessary to allow
other subsequent immunological interventions includ-
ing DLI and vaccination. If the relapse occurs while
a patient is receiving immunosuppressive therapy, the
drugs can be discontinued in order to induce
a GVHD/GVL flare. There is some risk that signifi-
cant GVHD will follow this maneuver. If the patient
Biol Blood Marrow Transplant 16:1467-1503, 2010 1469NCI First International Workshop on alloHSCTrelapses after immunosuppressants have been stopped,
a different strategy is required.DLI combined with TKIs
It is not clear whether addition of TKIs to this
treatment will improve or impair the immune response
of DLIs [19]. However, prior therapy with imatinib
does not seem to affect outcomes [20]. Patients that
were treated initially with alloHSCT for advanced dis-
ease may be treated with TKIs after transplantation to
prevent development of relapse. If despite this treat-
ment these patients relapse after transplantation,
further treatment with the same TKI does not appear
to be rational, unless it can be demonstrated that the
resistant clone has been eliminated by the transplanta-
tion. In such cases, administration of alpha interferon
may augment the immunologic response, and if
necessary, control the disease [21,22]. Whether or
not second-generation TKIs should be added to
DLIs is unclear [23,24]. In case of progression to AC
or BC, administration of second-generation TKIs, po-
tentially in combinationwith conventional chemother-
apy, may be necessary to control the disease, thus
allowing sufficient time for the DLI to exhibit its ther-
apeutic effect, which may take several months.DLI preceded by chemotherapy
Although relapsed-advanced CML is susceptible
to DLIs in a minority of cases without addition of che-
motherapy, it may be necessary to first control the
disease with chemotherapy, despite the vulnerability
of the hematopoietic system after transplantation. Sys-
temic chemotherapy or treatment with monoclonal
antibodies (mAbs) coupled to chemotherapy (eg gem-
tuzumab ozogamicin) can be used to control the dis-
ease and permit time to allow DLIs to exert their
therapeutic effects. Chemotherapy pretreatment may
not only control the disease, but may also provide
a ‘‘danger signal’’ to the immune system amplifying
the immune response. Furthermore, it is possible
that the lymphopenic phase following chemotherapy
may amplify the immune response because of homeo-
static proliferation of the immune cells infused. Treat-
ment of systemic BC may therefore preferentially be
comprised of chemotherapy rapidly followed by DLI
with or without TKIs depending on prior therapy,
possibly in combination with alpha interferon [14].
Although the combination of DLI and chemotherapy
may increase the likelihood of development of
GVHD [25], this risk may be preferred over the likeli-
hood of an insufficient response. Indeed, one could
categorize this approach as a form of nonmyeloablative
(NMA) transplantation. Administration of alpha inter-
feron may further augment the initiation of the im-
mune response [22].Major Unanswered Basic Issues in the
Treatment of Relapsed CML after alloHSCT
Defining the appropriate target antigens
Although DLI for relapsed CMLmay be highly ef-
fective, it can be accompanied by severe GVHD [4,26].
If immune suppression is necessary as treatment of
GVHD, it may severely impair the GVL reactivity.
Separation of GVL reactivity from GVHD is therefore
essential to improve outcomes. The clinical response to
DLI is likely to be dependent on the target structures
recognized by the donor derived T cells. Because
autologous HSCT and transplantation using stem cells
from syngeneic twins have not been found to be
associated with a clinically proven GVL effect, infusion
of T cells recognizing allo-antigens on recipient leuke-
mic cells is probably essential for the development of
GVL reactivity. T cells recognizing mHag, defined as
polymorphic peptides derived from intracellular pro-
teins and presented in the context of HLA molecules,
are probably responsible for bothGVHDandGVL re-
activity [8]. It has been hypothesized that T cells recog-
nizing mHag selectively expressed on hematopoietic
cells from the patient will cause GVL reactivity with
no or limited GVHD [27]. Alternatively, T cell
responses directed against tumor-associated, overex-
pressed self antigens like WT-1, proteinase-3, or
PRAME may also contribute to the antileukemic
effect. BCR/ABL specific T cell responses have been
reported to be generated in vitro, but clear high avidity
in vivo responses have not been demonstrated [28-30].
Characterization of the immune responses of patients
responding to DLIs with CRs in the absence of
GVHD may lead to better design of T cell
populations to be used for adoptive transfer.
Interference of TKIs with immune responses
Several reports have indicated that T cell reactivity
may be impaired in the presence of TKIs [31,32]. TKI
exposure may take CML precursor cells out of active
cell cycle making them less susceptible to T cell
mediated cytotoxicity. Furthermore, in vitro, TKIs
have been demonstrated to be capable of directly
inhibiting T cell function or inducing apoptosis of
activated T cells. Therefore, although TKI treatment
of molecular, cytogenetic, or hematologic relapse of
CML after transplantation may appear attractive to
control the disease, T cell-mediated cure may be
impaired by simultaneous treatment with T cells and
TKIs [19].
Incongruent clinical responses
Extramedullary relapses in the presence of clinical
CRs of CML in bonemarrow (BM) have been observed
following DLIs [16,17]. This may be because of the
inability of T cells to recognize the target structures
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recognition by inhibitory signals as provided for
instance by regulatory T cells (Tregs), or inability of
relevant T cells to home to the tumor site. Impaired
expression of human leukocyte antigens (HLA) on
hematologic tumor cells has been reported, but the
frequency is unknown [33]. However, the recognition
of mHag expressed only on subsets of CML cells, not
including the transforming tumor stem cell, may be a
cause of tumor escape. Detailed analysis of biopsies
from extramedullary tumors and the T cell responses
in these patients are necessary to unravel the biology
of this type of tumor escape. Local radiotherapy may
not only suppress the tumor, but also provide a danger
signal directing T cells to the tumor site.
In vivo induction of immune responses by
vaccination
Boosting the immune response specifically di-
rected against CML may be an attractive strategy to
amplify relevant anti tumor responses following trans-
plantation and/or DLI [28-30,34]. Vaccination studies
using tumor specific antigens (BCR/ABL peptide),
tumor-associated, overexpressed antigens (WT1,
proteinase 3, or PRAME), as well as peptides specific
for mHag such as HA1, are being explored to boost
the immune response. Especially in minimal residual
disease (MRD) circumstances when antigen presenta-
tion by the tumor cells is limited, amplification of the
(memory) immune response allowing immune surveil-
lance may be relevant. Careful functional characteriza-
tion of the immune response induced in vivo is
necessary to reveal whether the T cells recognize
antigens endogenously processed by the tumor, rather
than just low avidity peptide-specific reactivity that
does not contribute to antitumor reactivity. At present,
phase I/II studies are being undertaken to evaluate the
toxicity and possible efficacy of this approach.
Major Unanswered Clinical Issues on the
Treatment of Relapsed CML after alloHSCT
Cure or control
alloHSCT has been advocated as a curative treat-
ment of CML, but cure can only be achieved if the ma-
lignant stem cell can be destroyed. The immune
response generated in GVHD/GVL is likely to be
polyclonal, targeting multiple target antigens includ-
ing antigens expressed on CML stem cells as well as
on nontarget cells.Thus, when large numbers ofTcells
are infused, acute and chronic GVHD (aGVHD,
cGVHD)may lead to both early and late complications
that impair quality of life. A potential strategy to reduce
the risk of GVHD is to administer low-dose DLI late
after an initial T cell-depleted alloHSCT.T cell deple-
tion may lead to a more restricted GVL without
GVHD, with a higher likelihood of relapse, but whichthen may be successfully treated with repeated doses
of DLI. Hence, the ability to treat relapse is directly
relevant to the choice of initial therapy for CML. In
contrast, the ultimate goal ofTKI therapy is permanent
suppression of the P210 fusion peptide, not necessarily
cure of the disease. This appears to result in excellent
long-term outcomes with preserved quality of life.
These approaches have not been studied head to
head, so at present it is unclear which approach is
preferable.
DLI with or without TKI
Prevention of relapse after transplantation using
first or subsequent generation TKIs may appear to
be an attractive approach. However, administration
of TKIs may also impair the therapeutic effect of
DLIs. Therefore, if AP or BC are not likely to develop,
the overall high success rate of DLI alone or in combi-
nation with alpha interferon after transplantation may
favor postponing coadministration of TKIs [25]. In
a patient with a high risk of relapsing with AP or BC,
TKIs in the posttransplant period may be a reasonable
strategy, although a randomized study investigating
the use of TKIs after alloHSCT would be useful. Ar-
guments can be found both in favor and against simul-
taneous treatment of DLIs and TKIs [31,32,35,36].
Manipulation of the graft or DLI
Manipulation of the graft and/or DLI is the most
obvious approach to separate GVL from GVHD.
Complete T cell depletion of the graft to prevent
GVHD eliminates the initial GVL effect, but the
elimination of immune suppressive therapy after al-
loHSCT allows the postponed administration of
lymphocytes or lymphocyte subsets. Postponed ad-
ministration of DLI reduces the risk and severity of
GVHD, and may result in better quality of life after
treatment. Treatment with only CD41 T cells may
result in conversion into full donor chimerism with
limited risk of GVHD, although long-term follow-
up is needed [37]. Coadministration of Tregs may
reduce GVHD, but whether it will impair GVL needs
to be determined. Treatment with T cell products only
recognizing recipient hematopoietic cells is being
developed.Current Research Initiatives on the Treatment
of Relapsed CML after alloHSCT
The infrequency of alloHSCT for CML limits the
ability to perform large-scale clinical studies. There-
fore, careful monitoring of studies with limited num-
bers of patients will more likely give insight into new
strategies to more optimally treat patients with alloge-
neic transplantation and adoptive T cell therapy. A few
of the proposed major initiatives and questions on this
subject are described in the subsequent sections.
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Separation of DLIs into cellular subsets may main-
tain or increase the clinical efficacy against CML and
decrease the likelihood of developing GVHD. Al-
though it is not clear whether CML stem cells express
class II HLA during their cell cycle, most CML
progenitor cells highly expressHLA class II molecules,
whereas under steady-state conditions most nonhema-
topoietic tissues are HLA class II negative. Adminis-
tration of purified CD41 cells may therefore exhibit
GVL reactivity with limited risk of GVHD [37]. It is
also possible to activate T cells ex vivo to enhance
the GVL response [38].Targeting mHags or leukemia-associated
antigens by adoptive transfer
In vitro selection, activation, and expansion of
T cells recognizing mHag or leukemia-associated anti-
gens (LAA) may allow effective treatment of leukemia
after transplantation. Removal of T cells from the graft
and replacing them with antigen-specific T cells or
treatment with these purified cells instead of DLIs
may allow administration of high doses of tumor-
reactiveTcellswith amore limited risk ofGVL. In vitro
protocols allowing the isolation of antigen-specific
T cells under good manufacturing practice (GMP)
conditions urgently need to be developed for these pur-
poses. Further analysis of immune responses from
patients successfully treated with DLI in the absence
of GVHD will result in a better definition of mHags
and LAA that can be used to isolate tumor reactive
T cells for clinical use [27].Vaccination of patient or donor
Vaccination of the patient after transplantation
and/or DLI with mHags or LAA may boost the im-
mune response. Peptide vaccination has been shown
to be capable of boosting existing immune responses
in vivo. Because shortly after transplantation the naı¨ve
T cell repertoire is severely impaired, vaccination of
the patient with single antigens may have only limited
effect. Vaccination of the donor prior to harvesting of
the immune cells used for treatment may significantly
amplify the response and facilitate the isolation of
tumor reactive T cells from donor cells. Importantly,
vaccination of donors with mHags or tumor specific
antigens is expected to be harmless to the donor.
Another alternative is vaccination of the patient after
transplantation with a cellular leukemia vaccine de-
signed to stimulate a specificGVL response tomultiple
antigens [39]. The effectiveness of DLI may be im-
proved by the in vivo coadministration of recipient-
derived normal or CML-originated dendritic cells,
thereby exposing the T cells in the patient to a large
repertoire of mHags. Additional loading of thesedendritic cells by LAA of choice may further improve
the efficacy of the T cell responses initiated.
Multimodality therapy
Combining cellular immunotherapy and/or vacci-
nation strategies with TKIs after transplantation may
improve or impair the effectiveness. Randomized stud-
ies exploring the administration of TKIs are necessary
to analyze whether the use of these reagents will
decrease the likelihood of elimination of CML stem
cells, and prevent cure of the patient. Alternatively, in-
termittent treatment with TKIs may be explored to
more effectively combine short-term control of the
disease and long-term cure.
ACUTE MYELOGENOUS LEUKEMIA
Summary of Current Status
The principal cause of failure, and ultimately of
death of the patient, after transplant for acute myeloid
(a.k.a. myelogenous) leukemia (AML) is relapse.
Disease burden at time of transplant is the principal
predictor of recurrence. The definition of relapse after
transplant is itself likely to change [40]. The conven-
tional definition (BM showing .5% blasts on mor-
phologic exam) is most commonly used. However
patients with\5% blasts have been considered to be
in relapse based on recurrence of their initial
cytogenetic or molecular (egNPM1,WT1, FLT3) ab-
normality, or the presence of phenotypically abnormal
blasts as identified by multicolor flow cytometry. The
specificity of these types of ‘‘relapse’’ for subsequent
morphologic relapse is probably high but remains to
be documented more fully. Given the relation between
disease burden and outcome, these newer definitions
of recurrence are likely to have better prognoses than
morphologic relapses [41-43].
Disease tempo is likely to affect outcome of treat-
ment of morphologic relapse. Slowly evolving relapses
are more likely to have time for donor procurement
and for interventions other than chemotherapy to be
considered, whereas a rapidly evolving leukocytosis
at recurrence is likely to be treated with chemotherapy
(or not treated at all).
Long-term disease control occurs in 0% to 50% of
patients with AML who relapse after transplant. Much
of this variability is because of type and tempo of
relapse together with factors such as: (1) duration of re-
mission after transplant; (2) disease status at transplant
(remission patients performing better than those trans-
planted in relapse); (3) cytogenetics and/or presence of
NPM1 and/or FLT3 mutations; and (4) and donor
type (unrelated donors taking longer to provide DLI,
for example). Recipient age and presence of comorbid-
ities, including infections, are important consider-
ations shaping the ability to tolerate further therapy,
as is the presence of active GVHD at relapse.
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Withdrawal of immune suppression
Despite anecdotal reports of success [44], with-
drawal of immunosuppression (WIS) is very unlikely
(\5%) to result in clinically significant benefit, at
least in morphologic relapse. Disease kinetics is a ma-
jor predictor of response given the time required for
withdrawal to work. Responses with this approach are
most likely to occur in patients relapsing with a low
blast percentage, or with cytogenetic or molecular-
only recurrence. Presence of GVHD at relapse is
a major complicating variable, because any further
GVHD induced by stopping immunosuppressants is
unlikely to benefit a patient who was not ‘‘protected’’
against relapse by GVHD in the first place [45].
DLI
AML is of intermediate sensitivity to the GVL
effect, and as such, responses to DLI vary from 0% to
60%, with higher response rates reported for low
tumor burden, with the use of chemotherapy prior to
DLI, and in the context of T cell-depleted transplants
(notably with alemtuzumab) [6]. Most responses do
not translate into long-term survival, because of
GVHD, pancytopenia, infections, and disease relapse.
Donor availability (logistics are intrinsically more
complicated with an unrelated donor) and presence of
GVHD at the time of relapse are major impediments
[15,46-50].
Similar to what is observed when the recurrence is
treated with a second transplant (discussed later),
achievement of a CR after the infusion of lymphocytes
is a prerequisite for long-term survival. Survival is also
improved when relapses occur after longer remissions
(.6 months) [49,51]. Development of GVHD has not
been consistently associated with longer disease-free
survival (DFS) or overall survival (OS) after DLI,
a likely reflection of the competing risk of death be-
cause of the complication versus increased GVL effect.
Most series primarily include related donor DLI, but
unrelated donors are increasingly being used as well.
Analysis of unrelated donor DLI data is subject to 2
major biases. First, delays intrinsic to the procurement
process would indicate that patients so treated are
those whose disease is indolent or responsive enough
to allow the treatment to occur in the several weeks
necessary to perform the infusion. Second, the delay
may impose time for disease progression and for other
complications to occur, leading to worse outcomes. In
1 retrospective analysis of 23 patients, the CR rate was
42%, and 1-year DFS was 23%. The incidences of
aGVHD and extensive cGVHD rates were 35% and
40%, respectively, and 8% of the patients developed
BM aplasia [15].DLI preceded by chemotherapy
Use of chemotherapy appears to improve the
results of DLI [49,51]. Choice of chemotherapy
regimen varies widely, and it is impossible to make
specific agent recommendations based on published
literature. Response rates vary from 10% to 60%,
with higher response rates than those reported for
DLI alone.
The European Group for Blood and Marrow
Transplant (EBMT) reported a retrospective analysis
of 399 patients with AML in first hematologic relapse
after transplant, and compared patients that received
DLI (n 5 171) to patients that did not receive DLI
(n5 228). At a median follow-up of 27 and 40 months,
respectively for DLI and non-DLI patients, actuarial
2-year survival was 21% (63%) versus 9% (62%).
Improved survival was associated with younger age
(\37 years), longer duration of remission after
alloHSCT (.5 months), and use of DLI for salvage.
In the DLI subgroup, having less blasts in the BM
(\35%), female sex, presence of favorable cytogenet-
ics, and CR at the time of DLI were covariates associ-
ated with improved survival [51]. The benefit of
chemotherapy prior to DLI is suggested here by the
2-year survival .50% for patients that received DLI
in CR.
Special clinical situations using DLI for relapsed
AML
DLI after alternative donor transplants. DLI
is not an option after unrelated cord blood transplanta-
tion because the donor is not available. There is, how-
ever, preliminary experience withDLI after alloHSCT
from haploidentical related donors. In 1 series, 20
patients received granulocyte-colony stimulating fac-
tor (G-CSF)-primed DLI to treat relapse occurring
at a median of 177 days after alloHSCT. There were
8 survivors, and the incidence of severe GVHD was
apparently reduced by using GVHD prophylaxis after
DLI [52]. Rizzieri et al. [53] investigated early DLI
given after T cell-depleted NMA alloHSCT in 17 pa-
tients that received anHLA-mismatched related donor
transplant. Infusions were given at a median of 50 days
after alloHSCT, with amedian CD31 cell dose/kg of 1
 105. Severe aGVHD occurred in 14% of patients
receiving this cell dose. Long-term survival, however,
was achieved in only a few patients because of disease
relapse.
DLI in children with relapsed leukemia. A ret-
rospective analysis was conducted in 45 children with
relapsed leukemia, 21 of who had either myelodysplas-
tic syndrome (MDS) or AML, who were treated with
DLI with and without chemotherapy. Factors
associated with increased likelihood of achieving CR
included the use of pre-DLI chemotherapy and initial
posttransplant remission of at least 6 months. The
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patients from the Center for International Blood and
Marrow Transplant Research (CIBMTR) registry
with similar characteristics who did not receive
DLIs. After adjusting for the time from relapse to
DLI, there was no difference in survival between pa-
tients who received DLI and those who did not [54].
These findings suggest that any survival benefit from
DLI in children with relapsed AML is small. The use
of DLI in children outside of clinical trials should be
restricted to late relapses and be preceded by cytore-
duction.
DLI graft characteristics. Controversies in the
DLI setting include the use of G-CSF mobilized DLI
[55] to prevent BM aplasia, and the definition of an
‘‘ideal’’ cell composition. CD41 T cell enrichment
has been reported to decrease GVHD without com-
promising GVL [56,57]. The issue of cell dose is also
unresolved, and most of the prospective data has been
obtained in CML, a disease where a dose-response
relationship may exist. There is wide variation in the
literature, with mononuclear cell doses ranging from
0.1 to 10  108/kg, making a clear-cut recommenda-
tion impossible. Dose escalation is appealing for indo-
lent diseases, but may be of little practical value with
fully relapsed AML [11,58].
Chemotherapy
Attempts to assess outcomes in patients with AML
treated with conventional chemotherapy alone for re-
lapse after alloHSCT are hampered by the inability to
ascertain the patient characteristics that directed the
use of such therapy. Furthermore, reports on the use
of chemotherapy for relapse after alloHSCT at times
do not separate patients with AML, acute lymphocytic
leukemia (ALL), CML, or ‘‘high-grade’’ MDS, and
multivariate analyses do not consistently indicate that
results are not influenced by diagnosis. Nonetheless,
a sampling of the literature makes it clear that results
of conventional chemotherapy for relapse after al-
loHSCT are for the most part remarkably poor. A ret-
rospective analysis from the Fred Hutchinson Cancer
Research Center (FHCRC) using data collected from
1977 to 1984 indicated that 55 of 95 patients with re-
lapsed AML after alloHSCT received chemotherapy.
Thirty-two percent of the 34 patients given cytarabine
(with and without adriamycin) achieved CR with a me-
dianDFSof 9.7months [59,60]. The remission ratewas
highly influenced by time to relapse after alloHSCT,
such that the authors recommended that reinduction
be attempted only in patients relapsing at more than 1
year after alloHSCT. A multivariate analysis including
220 FHCRC patients relapsing after alloHSCT for
AML from 1995 to 2004, of whom approximately
75% received chemotherapy with and without WIS
therapy, confirmed the importance of time from
alloHSCT to relapse. Specifically 2-year survivalestimates for patients relapsing less than 100 days,
100-200 days, and greater than 200 days from
alloHSCT were 3%, 9%, and 19%, respectively.
Further demonstration of the direct relation between
the time from transplant to relapse and the
effectiveness of subsequent chemotherapy come from
papers by Levine et al. [49] and Choi et al. [61], both
of which explored the use of DLI after chemotherapy
for relapse following alloHSCT. The former reported
a1-year survival probability of 10%(95%confidence in-
terval [CI] 5 3%-31%) if relapse occurred within 6
months of transplant versus 44% (95% CI 5 29%-
68%) if relapse occurred later. These type of data led
Mielcarek et al. [59] and Levine et al. [49] much as it
didMortimer et al. [60] 15 to 20 years earlier to suggest
that standard chemotherapy, with and without DLI, be
used only in patients who relapse 3 to 6 months after
alloHSCT, with other patients being offered participa-
tion in clinical trials or palliative care if such trials were
not available.
The ability to identify AML patients at high risk of
relapse after alloHSCT together with the frequent
failure of therapies given only at relapse suggests that
such high-risk patients be treated with prophylactic
intent after alloHSCT. A major problem has been
that the candidate therapies have appeared either too
toxic or liable to abrogate a GVL effect if used at
such time. However, the introduction of less toxic
drugs has obviated this problem.
Azacitidine, which in addition to its anti-AML ac-
tivity may increase the immunogenicity of AML blasts,
provides the most instructive current example. de
Lima and colleagues [62] at the M.D. Anderson Can-
cer Center conducted a phase 1 trial of azacitidne as
posttransplant maintenance therapy in 42 patients
who underwent reduced-intensity alloHSCT for
relapsed/refractory AML. They found that starting
40 days, after alloHSCT azacitidine could be given
at 32 mg/m2/day for 5 consecutive days every 4 weeks
for at least 4 cycles without an untoward incidence of
GVHD (11% grade III, no grade IV) or other toxic-
ities, although dose escalation to 40 mg/m2 daily was
limited by thrombocytopenia. The authors have begun
a trial randomizing high-risk patients to azacitidine or
no maintenance therapy post-alloHSCT, although the
low risk associated with azacitidine suggests that its use
as antirelapse prophylaxis could potentially be ex-
tended to patients at lower risk of relapse. The M.D.
Anderson group has also treated patients with AML
and MDS relapsing after alloHSCT with low-dose
azacitidine. Preliminary experience indicates a 20%
long-term disease control rate for patients with ‘‘indo-
lent’’ relapses, without the need for immunosuppres-
sion withdrawal. This drug has also been investigated
with DLIs, or as a way to reduce disease burden prior
to alloHSCT, in the hope of improving transplant
outcomes [63-65].
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ple that other ‘‘less intense’’ drugs could be investigated
either at relapse following alloHSCT, or preferably, in
the prophylactic setting. A problem has been the
frequent reluctance of physicians, cooperative groups,
and pharmaceutical companies to even include patients
who have relapsed after alloHSCT in clinical trials.
Although there is understandable concern of toxicity
(and of interference with GVL in the prophylactic sit-
uation), the benefit to risk considerations would seem
to favor inclusion of at least some subsets of patients
with relapsed disease, if not patients at high risk of
relapse. Perhaps setting a precedent for such use, a clin-
ical trial of the aurora kinase A inhibitor C14005 (Mil-
lenium Pharmaceuticals, Cambridge,MA) for relapsed
AML includes patients in relapse after alloHSCT as
does a trial of FLT3 kinase inhibitor AC220 (Ambit
Pharmaceuticals, San Diego, CA). Patients with
FLT3 internal tandem duplications are at high risk of
relapse following conventional chemotherapy, and
hence, are likely to be disproportionately included
among patients given alloHSCT in first CR. In this
context, the activity of sorafenib, which can inhibit
not only FLT3, but also raf kinase and other receptor
tyrosine kinases, in 4 such patients in relapse after
alloHSCT is noteworthy as it resulted in 2 CRs [66].
However, the brief duration of these responses again
argues for prophylactic administration. Such a study
using AC220 was being planned at the time of this
publication. As the number of specific anti-AML ther-
apies increase,more patients should becomecandidates
for similar approaches. Among patients who lack a spe-
cific drug target, randomized designs might be
employed to suggest which nonspecific therapies are
most worthy of pursuing in larger trials [67].
Second allogeneic transplant
The likelihood of benefit from a second transplant
for relapsed AML is increased by achievement of CR
(or a lower disease bulk) prior to the second transplant
and a longer time from the first to relapse (often some-
what arbitrarily set at.6months). Younger age is ben-
eficial, as is the general health status of the recipient,
although this is less documented in large registry-
based retrospective analyses. There are no prospective,
multicenter trials in this setting, but available data
indicates that only a minority of relapsing patients are
treated with a second alloHSCT [43,45,68].
The presence of GVHD at relapse is a frequent
deterrent to any further cell therapy, including second
alloHSCT. The use of GVHD prophylaxis/treatment
during second transplant may minimize the impact of
GVHD (which may also be modulated by the chemo-
therapy itself), although this remains the topic of
debate among investigators.
Donor availability is a major issue after transplants
from volunteer unrelated donors or cord blood (CB).Second transplants from the same donor are not an op-
tion for CB, for example. Speed of procurement, on the
other hand, may be a major advantage for CB or
haploidentical transplants over volunteer unrelated
donors for those patients without HLA-matched fam-
ily donors, shortening the time to alloHSCT. Accord-
ingly, as with DLIs, the majority of second transplants
are performed for patients with a related donor. It is
unclear if a second transplant from a different versus
the original donor leads to improved outcomes. Most
reported studies are underpowered to answer this
question.
Available evidence suggests that the use of alterna-
tive donors for second alloHSCT is associated with
a relatively high treatment-related mortality (TRM).
A retrospective analysis by the CIBMTR looked at
279 patients with acute and chronic leukemias relapsing
after HLA-identical sibling alloHSCT who received
a second transplant [69]. The 5-year cumulative
incidences of TRM and relapse were 30% (range:
24%-36%) and 42% (range: 36%-48%), respectively,
whereas 5-year survival probability was 28% (23%-
34%). Risks of treatment failure and mortality were
lower in patients younger than age 20 years and in
patients with a CR duration of at least 6 months after
first alloHSCT. Longer remission after the first
transplant (.6 months) and achievement of CR prior
to second transplantation led to reduced recurrence
risk, whereas use of reduced-intensity conditioning
(RIC) regimen was associated with a higher risk of
relapse.
There are several controversial issues surrounding
the use of second transplants to treat AML recurrence.
Treatment of refractory relapses occurring early post-
alloHSCT outside of clinical trials is difficult to
recommend given current results. Whether the source
of stem cells, BM versus peripheral blood (PB), affects
outcomes is largely unknown. PB often has been used
because of a perceived higher GVL effect with this
source of hematopoietic stem cells; however, there is
also concern of increased GVHD with its use. The
choice of preparative regimen is often decided on the
basis of institutional preferences, prior therapy, and in-
vestigator experience. The use of NMA and RIC reg-
imens have gained popularity in this setting given high
TRM with myeloablative (MA) conditioning when
used for the second transplant, especially when the first
transplant used MA chemotherapy and/or radiation
therapy. The use of RIC regimens may be associated
with higher relapse rates; however, and the decision
guiding the choice of preparative regimen has to take
into account duration of CR after the first alloHSCT
(longer duration may allow the use of higher intensity
regimen), age, performance status, and other factors
usually employed to select patients for ablative chemo-
radiation conditioning. The uncertainty extends to the
GVHD prophylaxis regimen. Suboptimal GVHD
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hampered by prohibitive TRM/GVHD rates, and it
is unknown if any given regimen is better than any
other.
Natural killer (NK) cells
NK cell function is regulated by interactions be-
tween killer immunoglobulin-like receptors (KIRs)
present on the NK cells and major histocompatibility
complex (MHC) molecules present on the target cells.
Following highly encouraging findings from the
Perugia group demonstrating a strong protective effect
of donor NK cells on AML relapse in the T cell-
depleted haploidentical transplant setting [70], several
groups have explored the role of antileukemic effects of
NK cells in other alloHSCT settings. Reduced AML
relapse rates have recently been correlated with donor
NK cell properties in T cell-replete transplants using
related donors [71], unrelated donors [72], and NMA
conditioning [73]. At present, consensus has not yet
been achieved on how to reliably predict NK alloreac-
tivity, as several hypotheses have been advanced. The
original Perugia hypothesis, known as the KIR ligand
incompatibility model, suggested that NK alloreactiv-
ity could be predicted by comparison of donor and
recipient HLA class I genotypes. Subsequently, it be-
came recognized that NK cell alloreactivity is deter-
mined by the net effect of activating and inhibitory
signals transmitted between target cells and NK cells.
In alloHSCT, donor NK cells attack recipient cells
that fail to sufficiently engage the inhibitory KIRs. In
this model, NK alloreactivity can be predicted by com-
paring donor KIR genotypes (which are inherited in-
dependently of HLA genes) and recipient HLA class
I genotypes. However, even with improvements in
prediction of NK alloreactivity, numerous practical
questions regarding NK cell mediated antileukemic
activity remain, including the effects of the trans-
planted cell dose and chimerism. An even more crucial
issue for studies of NK cells for treatment of relapsed
AML is the present limited ability to generate the large
numbers of ex vivo clinical grade NK cells needed for
clinical trials [74]. Thus, although promising as a po-
tential antileukemia therapy, advances in NK cell
purification and production will be essential for future
clinical study.
Cytokines
The role of cytokines in treatment of relapse is un-
certain.Useof interferon-a, interleukin (IL)-2,myeloid
colony stimulating factors (eg, granulocytemacrophage
colony-stimulating factor [GM-CSF], G-CSF), and
combinations of these cytokines can be found in the
literature, generally as case reports or small trials [3].
Responses have been described, but long-term disease
control is unusual with cytokines alone.Treatment of extramedullary leukemia
Extramedullary (EM) relapse of AML following al-
loHSCT can occur simultaneously with medullary re-
currence or as an isolated site of relapse. It has been
suggested that EM relapses are more commonly diag-
nosed after DLI. Most studies of EM recurrence were
published more than 10 years ago, and the relevance of
these studies to current practice is not clear. In a review
of 78 consecutive transplants for AML, EM relapses
developed in 8 of 78 (10%) patients, evenly split be-
tween isolated EM relapse and concurrent medullary
relapse [75]. None of the patients had a prior history
of EM leukemia. Risk factors for EM relapse were
higher risk disease at time of transplant and absence
of GVHD. An analysis by the University of Michigan
(Levine, unpublished data) identified EM leukemia re-
lapse in 26 of 257 (10%) consecutive transplants for
AML performed at their institution between January
2001 and May 2008. All but 2 of these relapses were
isolated to EM sites. The median age was 48 years
(range: 0.6-69 years). Univariate analysis identified
several statistically significant risk factors for EM re-
lapse (Table 1). Two well-known risk factors for re-
lapse, high-risk cytogenetics, and high-risk disease at
time of transplant, were associated with an increased
risk of EM relapse. Patients with AML FAB morpho-
logic classification of M4 or M5, both of which are as-
sociated with EM disease, were more likely to
experience EM relapse than other subtypes of AML.
Interestingly, children (aged #18 years) were more
likely to experience EM relapse than adult patients.
A history of EM disease prior to transplant was not sta-
tistically associated with post-alloHSCT EM relapse,
although small numbers may account for this finding.
More than half of the 28 patients who had EM disease
prior to alloHSCT relapsed, 9 (32%) with EM relapse
and 4 (14%) with isolated BM relapse. EM relapses oc-
curred in a wide variety of sites including visceral
organs such as the lungs, skin, lymph nodes, and spinal
fluid, but the soft tissues were the most commonly
involved site. Treatment for EM relapse typically
included chemotherapy and/or radiotherapy alone
(n 5 13) or in combination with DLI (n 5 8). Despite
these measures, postrelapse remission was achieved in
only 6 (23%) patients. However, with a median of 13
months of follow-up (range: 9-70 months), these
remissions were durable without subsequent relapse.Conclusions on the Treatment of Relapsed AML
after alloHSCT
Current therapeutic modalities benefit a small
minority of patients who experience relapse of their
AML following alloHSCT.These are younger patients
with longerDFS, andwith good performance status. In
this subgroup, chemotherapy andDLI, with orwithout
a second alloHSCT are ‘‘standard options.’’ However,
Table 1. Variables Associated with Extra-medullary Relapse (University of Michigan Data)
Variable Hazard Ratio P-Value Variable Hazard Ratio P-Value
EM disease prior to TXP 1.150 .63 Related Donor 1.139 .52
Time from DX to TXP More than 6 Months 0.897 .59 HLA Mismatched 1.606 .08
High risk cytogenetics 1.574 .03 Sex Mismatch 0.930 .74
M4/M5 FAB classification 1.564 .03 PBSC Stem Cell Source 0.878 .59
High-risk disease at TXP 1.962 .001 TBI-based conditioning 0.644 .26
Age over 18 years 0.608 .04 Busulfan-based conditioning 1.597 .26
Full-intensity conditioning 0.832 .50
EM indicates extramedullary disease; DX, diagnosis; PBSC, peripheral blood stem cell; TBI, total body irradiation; TXP, transplant.
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reasonable to argue that all relapses after alloHSCT
are potentially eligible for clinical trials and should be
treated as such. Multicenter, prospective clinical stud-
ies are needed, and a list of obstacles and of potential
approaches is listed in Tables 2 and 3.Table 3. Critical Questions to Address for Patients with
Relapsed AML after alloHSCT
Potential to answer with a large database:
 Outcome of AML relapse after all forms of allogeneic HSCT, including
haploidentical and CB transplants.
 Result of DLI or second transplants after haploidentical and CB HSCT.
 Better definition of a patient population more likely to benefit from
‘‘aggressive’’ versus palliative care.
Potential to answer with prospective multicenter clinical trials and the use of
a sample repository
 Role of MRD detection in predicting relapse and defining need for further
interventions post-HSCT.
 Investigation of hypomethylation agents or ‘‘targeted’’ therapies to
prevent or treat relapse
 Better definition of MRD-defined relapse or persistent disease after
HSCT—treatment of molecular or flow cytometry-detected relapse
(without evidence of overt hematologic recurrence).
 Use of ex vivo expanded NK cells to treat relapse.ALL
Summary of Current Status
Relapsed ALL has a poor prognosis. Although
curative salvage treatment is possible in a minority of
children [76], the outlook for adults is particularly
dismal with only 7% of relapsed patients surviving at
5 years. This is regardless of age or prior therapy, as
well as duration of a prior first remission [77]. Relapse
after an allogeneic transplant is almost always incurable.
In practice, a cure following relapse after an
alloHSCT is almost always associated with a second
allogeneic transplant in childhood ALL. There are
some select survivors following a second allogeneic
transplant; a leukemia-free survival (LFS) of 21% at
2 years for patients transplanted in CR was reported
in an EBMT study [78]. Similarly, a Japanese study
reported a 19% LFS at 2 years; however, it was only
9% at 4 years [79]. There are only isolated reports of
such survivors in adults with relapsed ALL after
alloHSCT. TRM rates are extremely high, and enroll-
ment bias is likely. Age\16 years and duration from
first transplant to relapse of .6 months are associated
with better outcome. The impact of donor selection,
graft source, and conditioning regimen on outcome
of second transplant has not been fully elucidated
[69,80].Table 2. Key Obstacles for Development of Large, Random-
ized, Prospective Clinical Studies of Relapsed AML after
Allogeneic HSCT
 Lack of large, multicenter prospective phase I and II studies to define
experimental arms in a randomized study.
 Lack of large databases dealing specifically with relapse information.
 Lack of a broad discussion and consensus that should ideally involve drug
companies and the FDAon the need to enroll patients in phase I, II, or III
clinical trials for the treatment of AML relapsing after allogeneic HSCT.
AML indicates acute myelogenous leukemia; HSCT, hematopoietic stem
cell transplantation.Using currently available therapeutic modalities,
the few patients that may ultimately be cured are those
whose relapse occurs prior to the onset of GVL or
in the absence of GVHD posttransplant. Second
alloHSCT should involve careful consideration of
the appropriate donor. It may be the same donor.
However, if the patient developed GVHD, one might
argue that there was not an effective GVL response
and consider an alternative donor. If there was no prior
GVHD, a different donor may be considered, includ-
ing an unrelated donor. Alternatively, one could
consider a haploidentical donor (with T cell depletion)
in an attempt to useGVL that is not primarilymediated
byT cells (rather by othermodalities, such asNKallor-
eactivity, although this is not thought to be so potent in
ALL). Ciceri et al. [81] reported some success with
haploidentical transplants for ALL beyond first CR.
Another group that may possibly be cured is Phila-
delphia (Ph) chromosome- or BCR/ABL-positive ALL
patients who are not resistant to a TKI. Responses, Cord blood: ex vivo expansion of T cells.
 Ex vivo expansion of donor T cells through costimulation.
 Leukemia-specific DLI using antigen-specific cytotoxic T lymphocytes.
 Use of new technologies to inactivate alloreactive donor T cells.
 Use of new technologies to increase immune recognition (CARs, etc).
 DLI cell composition manipulation to decrease GVHD and
increase GVL.
 Cell of origin of relapse: recipient’s versus donor’s.
 Genetic profiling of relapsed AML.
AML indicates acute myelogenous leukemia; CB, cord blood; alloHSCT,
allogeneic hematopoietic stem cell transplantation; DLI, donor lympho-
cyte infusion; MRD, minimal residual disease; GVL, graft-versus-
leukemia; GVHD, graft-versus-host disease; CARs, chimeric antigen
receptors.
Biol Blood Marrow Transplant 16:1467-1503, 2010 1477NCI First International Workshop on alloHSCTincluding CRs, can occur and may be durable for
months or even years. Conventional chemotherapy
can prolong survival in selected patients, with long
transplant-to-relapse intervals and isolated EM re-
lapses representing prognostic factors for successful
remission induction [82]. This section will briefly
consider cellularmanipulations aswell as novel chemo-
therapeutic agents and targeted therapies for relapsed
ALL and will emphasize potential future directions.
Treatment Options for Relapsed ALL after
alloHSCT
DLIs
The GVL effect in ALL, contrary to common
perception, is probably 1 of the most potent strategies
with curative potential. This GVL effect in humans
was actually first described in patients undergoing an
allogeneic transplantation for ALL, as described in
the classic paper byWeiden et al. [83] in 1979. A num-
ber of nonrandomized studies have supported the
existence of a potent allogeneic GVL effect in ALL
[84-86]. In an Eastern Oncology Group/Medical
Research Council study in adults with ALL in first
CR,, GVL activity was unequivocally established. Of
239Ph-negative patients at standard riskwho had a sib-
ling donor, the relapse rate was 24% compared to 49%
in 333 standard-risk patients who did not have a donor
(P \.00005) [87]. Among Ph-negative high-risk pa-
tients, the relapse rate was 37% for the 204 patients
with a donor versus 63% for 261 patients without a do-
nor (P\.00005). Notably, increasing the intensity of
GVHD prophylaxis is associated with a higher risk
of relapse after alloHSCT in adults and children
with ALL [88,89].
Given the potent GVL effect in ALL, DLI is an at-
tractive therapeutic option for treating relapse after an
allogeneic transplant. In practice, unlike CML, they
are almost never effective in ALL in the state of florid
relapse. There are multiple factors that may limit the
effectiveness of DLI against ALL. Clinically, the rapid
proliferative rate of ALL is such that often the kinetics
of disease progression may outpace the duration
required to achieve a maximum GVL effect. Further-
more, unlike myeloid cells, B-lineage lymphoblasts
have very low expression of T cell costimulatory mole-
cules (eg, B7.1, B7.2), and thus present antigens poorly
and may induce T cell anergy [90].
CRs have occasionally been induced byDLI and/or
WIS for patients with ALL, although the reported re-
sponse rates of large series are quite poor, ranging
from 0% to 20% [4,15,48,91-99]. Although remissions
can be achieved, many are induced by the additional
use of chemotherapy, and are usually short lived, with
few long-term survivors [100]. As has been observed in
CML, the response rates of ALL to DLI are higher in
the setting of MRD (eg, molecular or cytogeneticrelapse) [101]. DLIs can induce remissions in approxi-
mately one-third of children with ALL prior to overt
relapse [102,103]. Because of the low likelihood of
achieving a durable CR, DLIs are not considered
standard for patients with ALL relapsing after
alloHSCT [104].
Second allogeneic transplant
As previously described, a second allogeneic trans-
plant is 1 of the few treatment options that provides
the possibility for long-term survival following relapse
of ALL after an alloHSCT.However, TRM rates asso-
ciated with second allogeneic transplantation are
extremely high. The utilization of NMA and RIC regi-
mens may reduce TRM associated with second trans-
plants and allow achievement of GVL-induced
eradication of residual ALL. Unfortunately, there are
very few data reporting RIC alloHSCT in ALL. The
EBMT published the outcome of 97 patients with
ALL who received RIC alloHSCT [105]. However,
there was a great deal of heterogeneity among the pa-
tients with varying RIC regimens. Clearly, some RIC
regimens were similar to what others would consider
as a standardMA conditioning regimen. A retrospective
analysis of 27 patients who receivedRIC alloHSCT, us-
ingdata from4prospectivemulticenter trials, attempted
to demonstrate whether there was a difference in relapse
rates between patientswho either did (n5 17) or did not
(n5 10) haveGVHD[106]. Although relapsewas lower
amongpatientswithGVHD, the analysiswas retrospec-
tive and the numbers were small. A similar report from
Japan [107] reported on RIC alloHSCT in 33 ALL
patients and also attempted to correlate the relapse
rate to the incidence of aGVHD and cGVHD; again
a nonsignificant difference was observed. Clearly, RIC
alloHSCT is feasible and can effect cures in patients
with ALL [108-110]. Important to this review,
a minority of the patients in the published series of
RIC alloHSCT represent second transplants to
manage ALL who have relapsed after a prior
allogeneic transplant, although some successes have
been reported [109].
Conventional chemotherapy and targeted
therapies
In patients with adequate performance status, re-
sponses may be achieved with standard ALL therapies,
or with newer agents such as clofarabine [111,112] or
nelarabine [113,114], or even with some of the less
toxic new formulations of existing drugs such as
liposomal vincristine [115]. The focus of new ap-
proaches will be on maintaining leukemia responses.
Paradoxically, imatinib and second generation TKIs
have been capable of inducing molecular CR after
alloHSCT and achieving prolongedDFSwith or with-
out DLI [116-119].
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The successes and limitations of DLIs in the man-
agement of posttransplant ALL relapse have led to
investigations of other forms of adoptive cellular ther-
apies after alloHSCT. For example, ex vivo expanded
cytotoxic T-lymphocyte clones (CTLs) that recognize
leukemia-associated antigen targets (eg, WT1) and
mHag may be active against relapsed ALL after
alloHSCT [6]. Notably, leukemia-associated anti-
gen-specific CTLs have been detected in normal
stem cell donors, raising the possibility that these
might be utilized to manage posttransplant relapse
[120]. Strategies have also been developed to enhance
lymphocyte effector functions, and posttransplant
clinical trials of a number of such approaches are being
conducted [121,122]. Antigen-driven oligoclonal pe-
ripheral T cell expansion has been shown to develop
during recovery from profound T cell depletion
[123]. Thus, the immune repertoire might be effec-
tively skewed toward tumor-associated antigens by
utilizing adoptive therapies in the early posttransplant
period, as has been observed in the autologous trans-
plant setting following lymphocyte-depleting chemo-
therapy [124]. Chimeric antigen receptors (CARs)
have been designed to enable immune effectors to
bind to and induce cellular cytotoxicity against ALL
blasts that express CD19 [125,126]. Clinical trials of
allogeneic T cells and NK cells engineered with
CD19-directed CARs are currently being evaluated
in clinical trials for children and adults with posttrans-
plant relapsed ALL.mAbs
Because mAbs were first generated against human
differentiation antigens there has been the expectation
that they would be used in the treatment of hemato-
logicmalignancies [127].MultiplemAb-based reagents
that target ALL-associated surface antigens have been
developed for investigation in humans.
Unconjugated mAbs. Unconjugated mAbs may
require functional immune effector mechanisms,
which are commonly deficient in the setting of
posttransplant relapse, and it is unlikely that unconju-
gated mAbs will have adequate single-agent efficacy in
most cases of ALL. However, rare cases of CRs of in-
dividuals with ALL have been reported with mAbs
targeting CD52 (alemtuzumab) and CD20 (rituximab)
[128-131]. mAbs against CD20 and CD22 have been
safely combined with standard chemotherapy in
the therapy of ALL and response rates appear
favorable in comparison to historical experience with
chemotherapy alone [132,133]. mAbs against CD20
and CD22 have been safely combined with standard
chemotherapy in the therapy of ALL, and response
rates appear favorable in comparison to historic
experience with chemotherapy alone [132,133].The use of mAbs that target tumor-associated
antigens might be useful in the treatment of relapse
after alloHSCT provided there are adequate effectors
capable ofmediating antibody-dependent cell-mediated
cytotoxicity (ADCC) [134]. Anti-CD19mAbs enhanced
posttransplant donor-derived mononuclear cell medi-
ated lysis ofCD191 lymphoblasts in a preclinicalmodel
[135].
Conjugated mAbs. The cytotoxicity of mAbs
can be dramatically increased by linkage to toxic moi-
eties such as chemotherapeutic agents, bacterial and
plant toxins, and radionuclides. Importantly, these
agents do not require functional immunity for activity,
and thus can be effective even in profoundly immuno-
compromised hosts such as after transplantation. The
anti-CD33 mAb linked to calicheamicin (gemtuzumab
ozogamicin), approved for use in AML but subse-
quently withdrawn by the manufacturer in the United
States for toxicity issues, has successfully induced CR
in cases of ALL with CD33 expression [136]. Studies
of recombinant anti-CD22 Pseudomonas-based immu-
notoxins in ALL have recently been conducted, and
activity and tolerability has been observed post-
alloHSCT [137]. The agent is synergistic with stan-
dard chemotherapy has been demonstrated, and
a Phase II trials with this combination are planned.
Radioisotope-conjugated mAb constructs that target
leukemia-associated or hematopoietic antigens (eg,
CD20, CD25, CD45) have been developed. These
are often associated with severe myelosuppression
and thus have been utilized as MA conditioning prior
to alloHSCT [138]. Targeted immunotoxins, such as
denileukin diftitox, which targets the IL-2 receptor,
have been studied in some lymphoid malignancies
[139] and may potentially also be effective in some
subtypes of ALL.
Bispecific mAbs. A recombinant anti-CD19/
anti-CD33 bi-specific antibody (MT103, blinatumo-
mab) has recently been shown to be active in hemato-
logic malignancies [140]. Large prospective clinical
trials are now planned. Importantly, these agents
recruit and thus require functional T cells for activity
and thus may have increased activity following
immune reconstitution after alloHSCT.
Cancer vaccines
A variety of leukemia-associated antigens including
tumor-specific translocation fusion products, lineage-
specific antigens, genes expressed aberrantly or in
higher than normal levels, histocompatibility antigens,
and viral-associated antigens have been utilized in novel
cancer vaccines. Studies of peptide vaccines have pre-
dominantly been conducted in the setting of myeloge-
nous leukemias [141]. The largest study of peptide
vaccination published to date represents a Phase I trial
of aWT1peptide administered withMontanide for pa-
tients withWT1-expressing hematologic malignancies
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logic malignancies including reduction in leukemic
blasts (2/10) andWT1 transcript levels (7/10). This ap-
proach is particularly appealing in the posttransplant
setting as toxicity is expected to be minimal. Molldrem
and colleagues [142] reported a case of successful PR1
vaccination for AML and posttransplant relapse. Den-
dritic cells and artificial antigen presenting cells can
be utilized in cancer vaccines to improve the immune
response to tumor-associated antigens [143]. To obvi-
ate the need to define target antigens and to avoid re-
striction to specific HLA alleles, autologous and
allogeneic tumor cell preparations can be employed as
an immunogenic source. ALL blasts can be used di-
rectly as an antigenic source (eg, apoptotic bodies or tu-
mor lysates) or they can bemodified to improve antigen
presentation. Investigators at the Dana-Farber Cancer
Institute have demonstrated that B-precursor ALL
blasts can be rendered capable of presenting antigens
by incubation with CD40 ligand and IL-4. However,
a clinical trial highlighted 2 important obstacles to vac-
cine therapy in ALL: the propensity for rapid disease
progression, and profound immune deficiency [144].
The application of such approaches to the posttrans-
plant setting, and the development of novel adjuvants
such as IL-7 and toll-like receptor agonists, offer prom-
ise. It is predicted that continued advances in tumor
immunology and immunotherapy will facilitate the
application of these approaches to the treatment of
relapsed ALL after alloHSCT.Conclusions and Major Research Initiatives on
the Treatment of Relapsed ALL after alloHSCT
Relapsed ALL following an allogeneic transplant
has a dismal prognosis, especially in adults. There is
a limited role for DLI, except possibly as prevention
of relapse in the setting of MRD. For those achieving
a secondCR,rare curesmaybeobserved followinga sec-
ond allogeneic transplant, and this approach should be
considered for younger individuals who relapse at least
6 to 12months posttransplant.Clinical trials are needed
to assess whether prolongation of response might be
achieved using cellular manipulations, attenuated
chemotherapeutic agents, and targeted approaches
such as mAb-based therapies. The challenge in this
area remains daunting. Prospective studies of novel
therapies should be performed to ascertain whether
early intervention prior to florid relapse might improve
the outcome for ALL that recurs after alloHSCT.NHL
Summary of Current Status
The term NHL encompasses a heterogeneous
group of diseases that range from indolent to highlyaggressive. Increasing evidence using NMA and RIC
regimens and Tcell-replete grafts demonstrates signif-
icant graft-versus-lymphoma activity capable of long-
term disease control for some histologic subsets of
NHL. The prognosis of patients with NHL relapsing
after allogeneic transplantation remains poorly de-
fined. The tolerability and efficacy of available treat-
ments often depend on tumor histology, conditioning
intensity, whether or not T cell depletion was used,
and the presence or absence of active GVHD. One
goal of salvage therapy would be to achieve remission,
potentially allowing GVT activity to establish disease
control. In the absence of GVHD, this may be
augmented by DLI. Chemotherapy treatments may
be better tolerated after alloHSCT following the
establishment of robust hematopoiesis from the graft.
mAb therapy may provide tumor reduction and poten-
tially augmentGVTactivity through enhanced antigen
presentation. Last, second transplants from alternative
donors following MA or RIC may be possible; how-
ever, significant TRM and generally poor disease
control are frequently observed.Factors Influencing the Outcome of Relapse
after alloHSCT
A large number of factors influence the outcome of
relapse post-alloHSCT and will be briefly discussed
here.
NHL histology
The clinical behavior of the underlying NHL has
a critical impact on the outcome of relapse post
alloHSCT [145]. Patients with aggressive NHL (T
cell or DLBCL or other high grade histologies) often
relapse with rapid growth kinetics and are chemother-
apy refractory to many agents. This leads to fewer
effective treatment options and treatment is often
palliative. DLI is frequently ineffective because of the
tumor out growing any attempted immune-mediated
GVT effects. In contrast, patients with indolent histol-
ogies (follicular, small lymphocytic, and others) may
relapse with slow-growing disease and be amenable
to treatment options such as DLIs, mAbs, WIS,
single-agent, or multiagent chemotherapy. These his-
tologies appear to be more frequently responsive to
GVT effects. Whether this is because of intrinsic sen-
sitivity or because of their slower tempo remains amat-
ter of debate. Mantle cell NHL, which clinically often
appears aggressive also appears to be quite sensitive to
GVT effects and in general responds like the other
indolent NHL’s.
Impact of prior therapy
Patients with chemorefractory disease at the time
of alloHSCTwho subsequently relapse also have fewer
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Figure 1. Survival of lymphoma patients relapsing after allogeneic
transplant, by time to relapse.
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when designing subsequent treatments.
Timing of relapse
Patients who relapse early posttransplant or grow
through aggressive conditioning regimens have a poor
outcome (Figure 1). Treatment is often limited to palli-
ative disease control. By contrast, those with late recur-
rences frequently can achieve further durable
remissions. Patients who relapse early following NMA
and RIC regimens have a greater number of treatment
options including antibody treatments, chemotherapy,
DLI, or consideration of second transplants from the
same or alternate donors. In this setting, consideration
of second transplant with higher risk MA conditioning
may be given.
Transplant conditioning intensity
The intensity of transplant conditioning also
effects the outcome and potential treatment options
in patients relapsing following alloHSCT. Relapse,
especially early followingMA conditioning, is often as-
sociated with rapid disease progression with relatively
few treatment options. DLI or nonhematopoietic toxic
agents such as mAbs may be considered. However, ag-
gressive chemotherapeutic combinations are usually
poorly tolerated. Second transplants following MA
conditioning have prohibitively high TRM and second
transplants using RIC and HCT have been associated
with poor disease control. Patients who relapse follow-
ing RIC or NMA alloHSCT frequently have a greater
number of options as discussed before, including con-
sideration of second alloHSCT.
T cell-replete versus T cell-depleted allografts
Manipulation of the allogeneic graft through in
vitro or in vivo T cell depletion can clearly decrease
the risk of significant GVHD. However, this has
been associated with a delayed onset of GVL effectsand a greater risk of early relapse. Using RIC regi-
mens, T cells are essential to induce GVT effects
[146]. In patients without GVHD, DLI can be consid-
ered with variable results, often dictated by disease
histology and the effects of prior therapy. Second
transplants may also be considered using T cell-replete
grafts. Patients receiving T cell-replete grafts have
higher rates of GVHD, but with a lower incidence of
relapse. Patients relapsing in the face of ongoing
GVHD are generally not candidates for DLI.
Treatment Options for Relapsed NHL after
alloHSCT
The management of relapse following alloHSCT
is complicated by many of the factors mentioned
before. The ability to treat and the effectiveness of
the salvage therapy is largely dependent on tumor
histology, chemotherapy sensitivity, patient comor-
bidities, and the presence or absence of GVHD.
WIS
Tapering or abrupt WIS is often the first attemp-
ted treatment for patients who have persistent or pro-
gressive disease early post-alloHSCT. This can only
be done in the absence of significant GVHD, and for
patients still on immunosuppressive drugs. To our
knowledge, the first observation of clinical benefit of
GVL effects in lymphoma was reported in a patient
with Burkitt’s lymphoma who relapsed after allogeneic
transplant and obtained a durable remission upon
withdrawal of cyclosporine [147]. Clinical benefits of
GVL effects have since been demonstrated in practi-
cally every subtype of lymphoma (reviewed by Grigg
and Ritchie) [148], but the frequency of responses
and their duration have been addressed in only a few
studies, summarized in Table 3. An early study de-
scribed a strategy of discontinuing immunosuppres-
sion followed by DLI (if no response) in patients
with relapsed or persistent disease following allogeneic
transplantation [149]. Four of 9 patients (both indolent
and aggressive histologies) responded to immunosup-
pression withdrawal alone. For patients with this op-
tion it should be considered. Risks include induction
of severe GVHD requiring therapy. The bulk of evi-
dence suggests that this is most effective in indolent
and mantle cell NHL. Although patients with aggres-
sive histologies may respond to immunosuppression
withdrawal, the rapid progression of disease in this
situation does not often allow GVT effects to regain
control of the disease. Thus, additional treatments
such as chemotherapy or radiotherapy are often added.
DLIs
Patients who are off immunosuppression and who
do not have GVHD may be candidates for DLI. This
has been associated with antilymphoma responses in
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reports are from cases presented in the context of larger
clinical trial results of transplantation. Antilymphoma
activity from DLI alone is more common in the indo-
lent histologies, but is also used following salvage che-
motherapy or radiotherapy and has been reported to
induce long remissions in some patients with aggressive
NHL histologies. Again, the risks of DLI appear to be
related to the induction of GVHD and resulting com-
plications of immunosuppressive therapy. Of note,
many of theCRs to immunologicmanipulations appear
durable, demonstrating theongoingbenefit ofGVTac-
tivity. Relatively few data exist regarding the relation-
ship between dose of DLI and response in lymphoma.
mAbs
Patients with B cell NHL who relapse following
alloHSCT are frequently treated with the anti-CD20
mAb, rituximab [150]. This treatment has minimal he-
matologic toxicity and is usually well tolerated. There
is some in vitro data that tumor cell killing via antibody
mediated pathways may induce GVT activity. In these
experiments, tumor cell lines that are opsonized by an-
tibody appear to have augmented presentation of anti-
gens to allogeneic T cells [151]. Rituximab use in
allogeneic transplantation may have beneficial effects
on cGVHD as well as disease relapse (reviewed by
Ratanatharathorn et al., 2009) [152]. Thus, for patients
with CD20 expressing B cell lymphomas who relapse
following alloHSCT, treatment with rituximab is
common. Details of the frequency of success are,
however, largely unknown.
Chemotherapy
For patients who are medically able to receive
treatment and who have either rapidly progressive or
bulky relapsed disease, additional treatments are
usually required to control their disease. Au et al.
[153] reported on the use of intensive chemotherapy
followed by infusion of hematopoietic stem cells
from the original donor to treat 5 patients who had re-
lapsed post alloHSCT. All patients initially responded
(4 CR), although only 1 was a long-term survivor. A
case study reported the use of irinotecan and immuno-
suppression withdrawal to successfully treat aggressive
NHL post alloHSCT [154]. There have been no
systematic studies on the success of this approach,
and examples are provided in the discussion of specific
histologic subtypes of NHL.
Radiation therapy
Radiation therapymay provide control of persistent
or localized relapsed disease post-alloHSCT.
Anecdotal reports of prolonged remissions with or
without DLI have been reported in the context of
alloHSCT trials. Behre and colleagues [155] describedthe activity of involved field radiation therapy followed
by DLI in 2 patients (diffuse large B cell lymphoma
[DLBCL] and marginal zone NHL) with local relapse.
Systematic evaluation of this approach has not been
reported.
Other immune manipulations
Other approaches aimed at augmenting the graft-
versus-lymphomaafter alloHSCThavebeenattempted.
Bashey et al. [156] used the blocking anti-CTLA-4
monoclonal antibody, ipilimumab, in a dose finding
study in 29 patients with relapsedmalignancy following
alloHSCT. CTLA-4 blockade may increase T cell
activity. Three patients with lymphoid malignancies
had objective responses (HL and mantle cell NHL). A
case report of the use of low dose thalidomide to induce
remission in a patient with relapsed DLBCL following
an MA transplant suggests that further study of these
types of approaches are warranted [157]. Additional
reports have suggested that treatment with IL-2 or
interferon alpha post-alloHSCT relapse may induce
GVHD and subsequent tumor control [158,159].
Second transplant
Theuse of a second alloHSCTas a salvage for a first
failed transplant has not been widely studied in NHL.
The use of an MA alloHSCT following prior high-
dose chemotherapy and an autologous transplant has
generally been poorly tolerated with a high TRM
[160]. A report from the EBMT registry in 114 lym-
phoma patients who underwent MA alloHSCT after
prior autologous transplantation demonstrated a 5
year OS of only 24% and progression-free survival
(PFS) of only 5% [161]. The disease progression rate
was 45% at 1 year and 70% at 5 years. Better results
seem to have been observed with NMA conditioning
regimens through the reduction in TRM. However,
there have been no prospective studies of second al-
loHSCT following a failed allograft. As discussed for
other diseases in other sections of this report, options
include the use of a different donor to stimulate more
GVT activity, including the use of mismatched,
haploidentical, unrelated adult donors or cord blood
cell products.
Outcomes in Specific Lymphoma Histologies
(Table 4)
Indolent (follicular) NHL
Patients with the indolent histologies ofNHLhave
generally been grouped together in most transplant
studies because of the large number of histologies and
the low incidence of each subtype. The largest studied
histology is follicular NHL and serves as the major
example of this group of NHLs. A report from the
M.D. Anderson Cancer Center included 2 relapsed
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[162]. Both achieved CR. The Seattle transplant con-
sortium also reported the outcome of 2 patients with
relapsed follicular NHL [163]. One received rituximab
and DLI and achieved a second long lasting CR
(21 years); another with progression early posttrans-
plant achieved a long lasting CR (41 years) following
WIS. The risk of relapse appears to be greater follow-
ing T cell-depleted grafts that can be offset by planned
T cell add-back or DLI [164]. Morris et al. [165]
reported responses in 6 of 10 patients receiving DLI
for relapse following transplantation with an
alemtuzumab-containing reduced-intensity regimen,
and Ingram et al. [166]/reported CR in 4 of 6 patients
receiving DLI for relapse following a more intensive
BEAM (BCNU, etoposide, cytarabine, melphalan)-
alemtuzumab regimen.
Thus, a reasonable strategy for patients with indo-
lent NHLwho relapse or have persistent disease in the
absence of GVHD is to consider WIS, mAb therapy,
and DLI. For patients not responding to this
approach, or those who have GVHD, treatment may
include antibody therapy, chemoradiotherapy with
the goal of obtaining a CR, and reestablishment of
GVT control. Second allogeneic transplants may be
considered, but have not been widely studied.
Aggressive (diffuse large B cell) NHL
Treatment of relapse of aggressive NHL following
alloHSCT is frequently difficult because of the rapidly
progressive nature of the disease. In addition, many pa-
tients are chemotherapy resistant, and themajority will
have failed high-dose regimens and autologous HSCTTable 4. GVL Induction in Non-Hodgkin’s Lymphoma for Patients
Study
Conditioning
for Original tx N Diagnosis Che
Donor Lymphocyte
Infusion
Russell 2005 [231] T-depleted 15
Non-T-depleted 2
17 MCL (4), FL (4),
CLL (4), DL (5)
Bloor 2008 [232] T-depleted 16 17 CLL 3; MCL 3;
FL6; T CL5
Bishop 2008 [169] RIC 5 DL
Van Besien 1997 [149] Myeloablative 3 DL(2), PL(1)
Marks 2002 [318] T depleted 15 FL (15)
Mandigers 2003 [319] T depleted 7 FL (5) SL (2)
Withdrawal of
immunosuppression
Van Besien 1997 [149] Myeloablative 9 DL(4)LBL (2)
FL (2) PL (1)
Bishop 2008 [169] RIC 13 DL
CLL indicates chronic lymphocytic leukemia; CR, complete remission; DL, dif
MCL, mantle cell lymphoma; mo, month; RIC, reduced-intensity conditioning;
leukemia; TCL, T cell lymphoma PR, partial response; SL, small lymphocytic lyprior to being considered for alloHSCT.Disease status
(partial or CR), chemotherapy sensitivity, disease bur-
den, and patient comorbidities are all important factors
having an impact on the risk of relapse in most studies.
Rezvani et al. [163] from the Seattle transplant consor-
tium reported on 6 patients relapsing after a very low-
dose NMAe regimen (fludarabine [Flu] and 200 cGy
total body irradiation). Two of 6 patients achieved
long-termCR (341 and 541months) following either
a second transplant or irradiation, rituximab, and ta-
pering of immune suppression. DLI was ineffective in
2 of the others. A report from Thomson et al. [167] in
patients receiving an RIC regimen containing alemtu-
zumab, Flu, and melphalan included information on 5
relapsing patients with primary DLBCL. Only 1 was
a long-term survivor (761months) following surgery,
irradiation, rituximab, and DLI. Sirvent at al. [168] re-
cently reported on the use of allogeneic transplantation
for patients with aggressive DLBCL in the French
transplant registry. Twenty of the 26 relapsed patients
died of disease, 5 remain in CR after treatment for
relapse with various combinations of chemotherapy,
radiotherapy, and DLI. In a series of 44 patients from
the Vancouver BC transplant group treated with MA
conditioning and alloHSCT, 13 patients progressed
or relapsed, and all subsequently died from disease
(3 received DLI).
The outcome of DLI or WIS for aggressive NHL
was reported in 15 patients with evidence of disease or re-
lapse by day 1100 post-allografting by Bishop et al.
[169]. Six of 11 patients treated withWIS orDLI alone
had responses, and 3 of 4 patients treated with chemo-
therapy and DLI responded. Six patients remained inwith Relapse After AlloHSCT
Preceding
mo/radiotherapy CR/PR Response
Response at Latest
Follow-up: Time from
Last DLI - Median (Range)
9 11 11 3-year PFS 52%, 3 yr OS of 58%
8 13 13 3 progressed and responded
to further DLI, 3 with
ongoing treatment, 10
in remission MFU 26 mo
after completing DLI (12-60)
4 3 3 ongoing CR 83+, 76+, 74+
0
? 8 7 ongoing CR med 31 mo
after DLI (16-40)
4 6 4 ongoing CR 43+, 49+, 80+,
89+mo
? 3 3 ongoing CR 2+, 20+, 22 mo
0 6 3 ongoing CR 63+, 42+, 44+
fuse large cell; DLI, donor lymphocyte infusion; FL, follicular lymphoma;
OS, overall survival; PFS, progression-free survival; PL, prolymphocytic
mphoma; yr, year.
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study by van Besien [149], immunosuppression with-
drawal led to responses in 2 patients with aggressive
NHL with persistent disease post-allografting.
Overall these results suggest that GVT effects may
be capable of promoting long-term responses in some
patients with aggressiveNHL, and that treatment of re-
lapse with aggressive salvage therapy (chemotherapy 6
radiotherapy) followed by DLI may achieve long-term
survival in a minority of relapsed patients.
Mantle cell NHL
There are very little data on the management of
relapsed mantle cell lymphoma following transplanta-
tion, partly because relapse rates may be relatively low
with T cell-replete protocols [170]. Khouri et al. [171]
reported induction of a complete response following
DLI in 1 of 3 patients relapsing following transplanta-
tion. Recent extension of these results has demon-
strated that the few patients who relapse early can
be induced to complete response by immunomanipu-
lation (rituximab 6 DLI or WIS) [172,173]. The use
of T cell depletion appears to increase the risk of
relapse, and requires T cell add-back or DLI in
many patients [165]. This suggests that mantle cell
NHL is quite sensitive to the impact of GVT effects
and that those patients who experience relapse or per-
sistent disease after alloHSCT should be treated with
approaches aimed at reducing immunosuppression,
mAb therapy, and consideration of DLI.
T cell lymphoma
An increasing number of studies have recently
been published evaluating the role of allogeneic trans-
plantation for the treatment of aggressive T cell malig-
nancies. Shiratori et al. [174] reported on 15 patients
with adult T cell leukemia/lymphoma treated with al-
logeneic transplantation. Four of 6 patients with per-
sistent or relapsed disease responded to abrupt WIS.
Small series suggest graft-versus-lymphoma activity
following both RIC and MA conditioning in patients
with peripheral T cell NHL, with some evidence of re-
sponse to immunosuppression withdrawal for a minor-
ity of patients who progress/relapse [175,176].
Kyriakou et al. [177] analyzed the outcome of
alloHSCT for patients with angioimmunoblastic T
cell lymphoma reported to the EBMT. Eight of 45 pa-
tients progressed or relapsed, and 2 of 2 responded to
DLI with long-lasting CR. One patient who relapsed
following an NMA transplant did well following a sec-
ond MA allograft.
Currently, there does appear to be evidence of
graft-versus-lymphoma effects in patients with T cell
lymphomas. For patients who relapse following
alloHSCT, treatment with immunosuppression with-
drawal, DLI, with or without chemotherapy should
be considered.Unanswered Questions in the Treatment of
Relapsed NHL after alloHSCT
Most of the information on the fate of patients
with NHL relapsing after allogeneic transplantation
is anecdotal and all of it retrospective. Prognosis of
individual patients relapsing after allogeneic transplan-
tation is not well defined, although in cases of late
recurrences, and particularly for those with indolent
histologies, a number of effective interventions may
exist.
Most interest has been in the investigation of DLI
or modified DLI infusions, but optimal dose and
schedule remain to be defined. The majority of infor-
mation on DLI has been obtained in T cell-depleted
transplants, and these may represent a quite different
biologic stratum than those undergoing T cell-replete
transplants.
The observation of responses to WIS to potent
GVL effects; but similarly durable responses to often
modest chemotherapeutic interventions are interest-
ing. Many patients have persistent donor chimerism
at the time of disease recurrence, and it is likely that
GVL effects remain operative and amplify the benefits
of chemotherapy. This suggests that aggressive ap-
proaches to obtain subsequent remissions should be
considered. In addition, strategies aimed at triggering
enhanced GVT activity through the use of immune
modulating agents appear promising.
Proposed Major Initiatives on the Treatment of
Relapsed NHL after alloHSCT
The most urgent issue in lymphoma is to develop
national and international collaborations for prospec-
tive studies in more homogeneous and larger patient
populations. DLI and cellular interventions are of
major interest but chemotherapeutic interventions
also provide tantalizing clues and may be more practi-
cal. Most patients relapsing after allogeneic transplan-
tation are excluded from studies of novel agents
because of the mere fact of having undergone the allo-
geneic transplant or because of lowblood counts. In ad-
dition, pharmaceutical companies are reluctant to
include these patients as they have a high rate of ongo-
ing complications and toxicity related to their prior
therapy. These restrictions need to be carefully consid-
ered because often unsubstantiated exclusions can de-
prive patients of potential major benefits and the drug
industry of potential novel observations [178,179].HL
Summary of Current Status
The high TRM (range: 43%-61%) that has been
associated with alloHSCT using MA conditioning to
treat HL (a.k.a. Hodgkin disease) has both restricted
1484 Biol Blood Marrow Transplant 16:1467-1503, 2010D. L. Porter et al.the number of patients undergoing allogeneic trans-
plantation and reduced the number of patients
surviving long enough to relapse [180-183].
Therefore, despite the relatively high relapse rates in
surviving patients, there is very little experience
reported in managing relapsed patients following
ablative transplantation. The use of NMA and RIC
regimens have greatly reduced the TRM associated
with allografting for HL (range: 3%-25% at 1-3
years), and disease relapse is now the most common
cause for treatment failure (range: 44%-81% at
2-3 years) [145,184-188]. Therefore, there is
accumulating data on treatment approaches for
relapsed HL; this also provides an increasing
population in whom questions concerning appropriate
therapeutic strategies for relapse must be addressed.
To date, however, there has been no consensus
regarding these issues, often with no prescriptive
guidance within prospective series.Treatment Strategies for Relapsed HL after
alloHSCT
The 2 major current strategies used to treat
relapsed HL have been salvage chemoradiotherapy
and/or DLI. The published literature is essentially
unhelpful in providing an evidence base to guide prac-
tice, as salvage chemoradiotherapy regimens are often
not reported in detail and vary considerably evenwithin
single series. Response rates likely reflect disease-
related features (eg, prior therapy, chemotherapy sensi-
tivity at transplant, time to relapse, tempo of relapse),
with no current suggestion that any particular regimen
is likely to affect a cure.
Experience with DLI, largely restricted to unma-
nipulated T cells, provides increasingly persuasive
support for the existence of a graft-versus-HL effect
(Table 5) [189]. Response rates have been broadly
consistent between series with an overall response
rate of 43% and CR rates of 29% in cases where
such information was provided, although interpreta-
tion of immune responsiveness is often complicated
by administration of salvage chemotherapy or radia-
tion prior to DLI. Responses have been durable in
a small but significant number of patients (approxi-
mately 25%). These figures are supported by an
EBMT registry-based report, which clearly has some
overlap in terms of reported patients [190]. Although
specific details are more restricted, the response rate
was 32%, and an additional 15% was reported to
have either stable disease or brief clinical responses.
In the 18 patients treated with DLI alone, the response
rate was 44%. With HL, there is evidence to suggest
a correlation between T cell dose and both the
development of GVHD and disease response
[184,191,192]. It is not clear whether there is actually
a dose-response or dose-toxicity relationship or morelikely a minimal threshold dose that needs to be
achieved. The optimal CD31 T cell dose for DLI
purposes, however, remains unclear and varies
among different reports, and interpretation of individ-
ual cases is further complicated by the influences of
donor source, degree of HLA-mismatching, and prob-
ably also time from transplantation on post-DLI
outcomes.Unanswered Questions on the Treatment of
Relapsed HL after alloHSCT
Given the relative scarcity of reported experience,
it is little surprise that most questions regarding opti-
mal management of relapse of HL post-allograft re-
main unanswered. Reliable predictors of durable
DLI responses would clearly be helpful in planning fu-
ture exploratory interventional studies. Factors such as
the influence of tumor histology on outcomes, and the
role and optimal type of salvage chemoradiotherapy
remain unknown. The role of newer salvage agents
such as gemcitabine, alone or in combination with cel-
lular therapies, could be addressed in prospective stud-
ies. mAbs are of potential interest as salvage agents,
and these might augment DLI responses. Thus, anti-
CD20 mAbs could be evaluated in CD201 nodular
lymphocyte predominant cases. Relatively few of these
cases are likely to be transplanted because of the rela-
tive rarity of this histological subtype and the high
cure rates with conventional approaches, suggesting
that multinational studies would be required to assess
efficacy. Other mAbs, which are currently being as-
sessed for therapeutic activity in relapsed HL, include
anti-CD25 and anti-CD30, both of which may be
more effective if used as vectors for delivery of radio-
conjugates or cytotoxics such as calicheamicin.
Most of the durable salvage responses reported to
date have followed DLI in the setting of T cell-
depleted transplants, although whether this is a critical
factor remains unclear. Mixed chimerism is more com-
mon following T cell-depleted transplants. In murine
models the presence of mixed chimerism of recipient
derived antigen-presenting cells (APCs) has been sug-
gested to be important in supporting GVT responses
following DLI, but the issue remains contentious in
the setting of clinical studies in humans. Rates of
GVHD are also lower following T cell depletion
[193], and it is possible that patients relapsing follow-
ing T cell-depleted transplants represent a biologically
different population than those relapsing following T
cell-replete transplants. In the latter case, relapse
might reflect a failure of alloreactivity, predicating
a low chance of long-term response to DLI. In con-
trast, relapse following T cell depletion might reflect
an untested GVT effect, particularly in those without
GVHD (associating with mixed chimerism). It is
also possible, however, that the differences reflect
Table 5. Donor Lymphocyte Infusions for Patients with Relapsed Hodgkin Lymphoma after alloHSCT
Study N Preceding Chemotherapy CR/PR Response Rate Response Rate (DLI Only)
Response at Latest Follow-up: Time
from Last DLI - Median (Range)
UK [184] 16 3 8/1 56% 54% 5 CR 2223 days (1851-2388)[320]
Spain [186] 11 3 3/3 55% N/A None ongoing
UMN [188] 2 unknown 0/2 100% unknown None ongoing
GITMO [187] 12* 3 3† 33%* 33% unknown
MDACC [192] 14 11 3/3 43% 33% 1 PR 264 days
DFCI [145] 13 unknown 2/0 15% unknown unknown
EBMT Registry 41‡ 23 13b 32% 44% unknown
alloHSCT indicates allogeneic hematopoietic stem cell transplanatation; DLI, donor lymphocyte infusion; CR, complete remission; PR, partial remission.
*Twelve received DLI for relapse, 3 with prior chemotherapy who were reported as not evaluable for response.
†Overall response rate, not reported separately as CR/PR rates.
‡Sixty-four patients received DLI for relapse/progression but data follow-up data are available on only 41.
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transplantation) unrelated to transplant conditioning.
All of these issues could potentially be addressed in
prospective studies.
The identity of the targets relevant to immunologic
responses remains unknown. As with other hematologic
malignancies, establishing the identity of these targets
remains an imperative for development of potentially
safer adoptive cellular therapeutics and/or vaccination
strategies. There is now compelling evidence that
Epstein-Barr Virus (EBV) may contribute to the patho-
genesis of a significantnumberof cases ofHL [194-196].
EBV-associatedHL, incontrast toclassicposttransplant
lymphoproliferative disorders, express a less immuno-
genic profile of latent phase proteins including EBNA-
1, LMP-1, and LMP-2a [197,198]. Initial experience
with adoptive transfer of EBV-specific T cells into
patients with EBV-associatedHL has provided provoc-
ative inferential evidence that some tumorsmight be tar-
geted by the immune system in this way [199]. Because
the cellular product was generated by culture on large
B cell lymphoma cells, the majority of the EBV-
specific T cells had specificities other than LMP-1 and
LMP-2, but the LMP-2-specific subsets were found to
expand in vivo following transfer, contribute to the
memory pool, and to traffic to tumor sites, providing
the impetus for subsequent attempts to optimize the
generation of LMP-2-specific cellular products [200].
Overall, this experience thus hints that EBV-associated
antigens could be potential immunologic targets for
GVT activity in those with EBV-associated HL. How-
ever, the majority of patients receiving allogeneic trans-
plants will fall into the young adult category, presenting
mainly with nodular sclerosing histology, and with
relatively few EBV-associated cases [184].
The majority of experience with DLI to date has
been with unmanipulated lymphocytes. Whether
selection of specific subsets (eg, CD81T cell depletion
or CD41 T cell selection), or other manipulation, in-
cluding nonspecific activation and expansion through
costimulation [24] offers any advantage is probably
a more generic issue that should be considered outside
the setting of disease-specific studies. Redirection ofT cell specificity with either T cell receptors or
CARs, targeting either EBV-specific antigens in the
small subset of appropriate cases or perhaps CD30 is
a further possibility [201].
All salvage strategies are potentially toxic. Func-
tional imaging (eg, FDG-positron emission tomogra-
phy [PET]), particularly in combined modality with
computed tomography (PET-CT) analyses, may both
limit inappropriate therapy for equivocal residual
posttransplant masses, and allow earlier intervention
prior to the development of significantly increased
volume on CT scans [202]. Again, it remains unclear
whether this will improve overall outcomes, but it is
an area that warrants further study.Proposed Major Initiatives on the Treatment of
Relapsed HL after alloHSCT
Evidence supporting a potent allogeneic graft-
versus-HL effect is increasingly compelling. Many of
the issues treating relapsed HL overlap with those in
other disease types, and the value of trying to
enhance activity of cellular therapies across disease
types needs to be explored. In HL, addressing critical
issues related to timing of intervention, factors
predictive of response, appropriate cell dose, and
long-term outcome after relapse, will require multi-
center collaborations rapidly testing new interventions
and adopting uniform treatment strategies. Forming
international collaborative trial groups for this pur-
pose should be a major goal to improve outcomes for
patients with relapsed HL.CLL
Summary of Current Status
Relapse, including disease progression or recur-
rence, is a major cause of treatment failure after
alloHSCT for CLL, affecting up to 50% of patients
[203-209], or more in some subgroups [206,210].
Successful treatment of CLL relapse after
allotransplant has been reported, including durable
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approach to therapy and the frequency and duration
of response [165,203,205,207,211].
There are few studies that directly address progno-
sis after allotransplant in individuals with CLL
progression or relapse. In a study of NMA transplant
forCLLnearly one-third of thosewho failed to achieve
remission remained alive at median follow-up of 29
months (range: 11-66 months) [203]. This lengthy
survival in patients with suboptimal response to allo-
transplant is consistent with a GVL effect.
The pattern and time of relapse suggests different
mechanisms of failure. Very early progression or
relapse after transplant often reflects inadequate tumor
control with conditioning, with unabated disease
progression prior to maturation of the donor immune
system and establishment of GVT. In such cases ther-
apeutic strategies to augment GVT may be effective.
In contrast, relapse shortly after remission following
conditioning may reflect inadequate GVL ability to
sustain the initial response. Efficacy of efforts to boost
a donor antitumor immune response would be influ-
enced by potential reversibility of the GVL deficiency.
Reduced PFS has been noted in recipients of T
cell-depleted allografts [206,212] and those with
longer duration of mixed hematopoietic chimerism
[205,207]; both clinical scenarios are potentially
addressed by WIS and DLI. Persistence of MRD after
transplant and withdrawal of immune suppression are
also associated with poor PFS, and may indicate
patients with a qualitative GVT defect that would be
less likely to respond to immunomodulation [213].
Relapse of CLL can be seen many months or years
after allotransplant [203]. Such late relapse may reflect
loss of established GVT control, plausibly because of
clonal evolution of CLL, and ‘‘immune escape.’’ Con-
sistent with this are observations that tumor behavior
is altered in relapse after transplant, noted in CLL
and other malignancies [17,214-216]. Additionally, it
is worth considering whether late recurrence might
represent de novo CLL of donor origin. Donor-
derived CLL presenting as a late relapse has been
reported, as have donors with a relatively common
precursor state, monoclonal B cell lymphocytosis
(MBL) [217,218]. MBL clones can be detected in up
to 18% of unaffected members of ‘‘CLL families’’
and more than 5% of the general population over 65
years [219-223]. Thus, transfer and subsequent
development of donor-derived CLL is plausible after
transplantation with either related or unrelated do-
nors. Intuitively, whether because of clonal evolution
with development of ‘‘GVL resistance’’ or transfer of
a donor clone, late relapse may be less responsive to
immune manipulations, including WIS and DLI. Par-
adoxically, if late relapse indicates a new or trans-
formed clone, it may be more sensitive to cytotoxictherapy than prior tumor behavior would otherwise
indicate.
Treatment Options for Relapsed CLL after
alloHSCT
DLI
There is significant circumstantial evidence for
GVT in CLL that includes observations of lower
relapse rates after allogeneic versus autologous trans-
plantation [224], decreased relapse in patients who
develop cGVHD [224,225], increased relapse in
recipients ofT cell-depleted allografts [226]with subse-
quent response to delayed DLI [224], and delayed
responses after NMA transplantation [179,226].
Therefore, in the absence of significant GVHD,
initial treatment for CLL progression or relapse is
often with withdrawal of immune suppression and
DLI, maneuvers that have been reported to induce
durable complete responses [205,226,227].
Broad interpretation of the DLI literature for CLL
response is limited by heterogeneity of factors that in-
fluence efficacy, such as disease status, donor chime-
rism, and indication for DLI (mixed chimerism with
persistent disease, disease progression with full donor
chimerism, etc.), and of DLI products (subset enrich-
ment, cell dose, etc.) [4,54,104,228-230]. Widely
disparate results likely reflect this heterogeneity. In
some series, efficacy of DLI for relapsed lymphoid
malignancy was as high as 75% in indolent tumors,
including CLL [104,231,232]. Responses were far less
frequent in others (Table 6). For example, Khouri
et al. [205] reported on 10 patients with CLL treated
with NMA allotransplant and planned WIS followed
by DLI for persistent disease at day 100. Three
responded to WIS without DLI. Six of 7 patients who
received DLI responded; 8 of 9 responders had also
received rituximab. In contrast, in a report on 64
patients treated for chemotherapy-refractory CLL
with NMA alloHSCT [211], only 1 of 6 patients with
CLL progression responded to DLI (5 of whom also
received chemotherapy) [203].
The importance of disease status onDLI efficacy is
illustrated by use of planned DLI for treatment of
persistent or progressive disease after T cell-depleted
allotransplant. Hoogendoorn et al. [212] reported on
12 patients with advanced CLL treated with RIC and
ex vivo alemtuzumab-depleted allografts; at 6 months,
those with persistent disease or mixed chimerism were
given DLI. Additional DLI at escalating doses were
permitted in the absence of GVHD. Although none
of the 7 patients with progressive disease responded
to DLI, 4 patients with DLI for persistent disease
achieved durable CR. In a similar approach, Delgado
et al. [204] reported on 41 patients with CLL treated
with RIC allotransplant, with systemic alemtuzumab
Table 6. Reported Outcomes for DLI in CLL Progression after AlloHSCT
Reference N (CLL/Total)
DLI Response
CR/PR/PD
Adjunctive
Rx CR/PR/PD Notes
Russell 2005 [231] 4/17 3/0/0 0/–/– 4th patient likely CR; not evaluable for response because
of aplasia after DLI, required 2nd SCT/DCR. All developed GVHD
Ritgen 2004 [321] 3 2/0/1 0/–/0 9 NST for CLL/Unmutated VH 5 cGVHD/ MRD
neg (no DLI) 3 DLI for MRD
Gribben 2005 [322] 7/7 6/0/1 0/–/0 Myeloablative, TCD-SCT CD8-Depleted DLI. [37] GVHD 50%
Marks 2002 [318] 8/81 0/1/7 –/0/0
Sorror 2005 [211] 6 0/1/5 –/0/4 PR/ GVHD/ death 4 received various CLL treatments prior to DLI
Khouri 2004 [205] 7/7 4/2/1 3/2/0 No relapse at median 10 months Adjuvant rituximab in 5/7 3 WIS/
GVHD/ CR (no DLI)
Delgado 2006 [204] 14 5/1/8 1/0/5 2 GVHD deaths in responders
ND indicates no data;WIS, withdrawal of immune suppression; CR, complete remission; DCR, durable complete response; aGVHD, acute graft-versus-
host disease; cGVHD, chronic graft-versus-host disease; OS, overall survival; EFS, event-free survival; MRD, MRD, minimal residual disease; CLL, chronic
lymphocytic leukemia.
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mixed chimerism or persistent disease were treated
with escalating doses of DLI. Responses were seen in
1 of 3 patients who received DLI for persistent disease
and in 3 of 11 patients with progressive disease.
Although it is difficult to draw definite conclusions
from these and other studies, they clearly indicate the
biologic potential of GVL effects in CLL. Further
studies are needed to determine the optimal indica-
tion, timing, and dose of DLI, to identify those most
likely to benefit, and to define criteria for addition of
adjunctive CLL treatment. For example, MRD moni-
toring might be useful as a means of identifying opti-
mal timing and patient selection. Ritgen et al. [213]
have described 5 distinct patterns of MRD kinetics
after allotransplant; assessing DLI responses and
toxicity with respect to these patterns of MRD kinetics
may permit prediction of CLL sensitivity to GVL
versus ‘‘secondary graft-versus-CLL resistance,’’ with
potential implications for DLI failure.
Augmented DLI
Separation of GVL activity from GVHD, the
‘‘Holy Grail’’ of allotransplant research, has influenced
efforts to improve outcomes after DLI for CLL. In
some cases, CLL cells may inhibit a potential cell-
mediated antitumor effect. Multiple immune defects
have been described in untreated individuals with
CLL and may contribute to GVL failure of the trans-
planted immune system. Imbalances in T cell subsets,
diminished T cell signaling response, suppressed NK
cell function, and maturation and functional defects
of APCs are among the potential culprits that have
been described [233]. Porter and colleagues [122] hy-
pothesized that inadequate costimulatory signaling
may contribute to ineffective GVL activity and that
providing CD3 and CD28 costimulation of donor
lymphocytes ex vivo would produce an activated T
cell product (aDLI) capable of initiating a GVL re-
sponse. A phase I dose-escalation trial demonstrated
the feasibility and safety of a DLI following unmanip-
ulated DLI in patients with relapsed disease afterallogeneic transplantation, including a patient with
CLL who remains in CR for more than 5 years [234].
Another approach under investigation is directing
donor T cells to cell surface antigens found on malig-
nant cells. Bi20 (FBTA05) is an engineered antibody
with bi-specificity forCD20 andCD3 and trifunctional
recruitment of B, T, and FcgRI1 accessory cells,
hypothesizing that colocalization of tumor and T cells
would improve GVL responses. Buhmann and
colleagues [235] tested Bi20 in combination with DLI
or stem cell-mobilized donor PB mononuclear cells
(mobilized DLI) in previously allotransplanted pa-
tients. This trial included 3 subjects with treatment-
refractory, p53-mutated CLL. All showed a transient
clinical response with improvement in B symptoms,
lymphadenopathy, splenomegaly, and clearing of
leukemic cells from the blood with increasing doses
of Bi20, but progressed following discontinuation of
Bi20-DLI. Another strategy is genetic engineering of
donor T cells to express CARs to B cell antigens (eg,
CD19) along with costimulatory signaling molecules.
Early reports are promising in preclinical studies
[236] and in treatment of B cell malignancies in the
autologous setting. Clinical trials assessing the safety
and efficacy of CD19-CAR-transduced donor T cell
therapy for allotransplant relapse are underway.
Serious inflammatory-mediated toxicities after CAR-
transduced T cell transfer have been reported
[237,238], which may be target- and/or construct-
dependent, and/or result from immune-depleting
preparative regimens used in autologous adoptive
cell therapies. Concern that inflammatory responses
could result in GVHD toxicity in the allogeneic
setting has led Cooper and colleagues [239] to develop
an approach to alloanergize CAR-transduced donor
T cells.
Dendritic cell (DC) vaccines
DC vaccine approaches are being explored for
CLL, with clinical trials showing promise using
apoptotic whole-cell autologous DC preparations
[240,241]. Effective vaccines may be a useful adjunct
1488 Biol Blood Marrow Transplant 16:1467-1503, 2010D. L. Porter et al.to DLI [242]. Whole-cell preparations may have ad-
vantages in the allogeneic setting, allowing the poten-
tial for GVL activity against multiple cellular proteins.
Alternatively, antigen-specific DC vaccines might be
useful in patients with relapse and GVHD,more effec-
tively targeting an augmented GVL response. Survivin
is a ‘‘universal tumor antigen,’’ found on many tumor
types, including CLL, as well as normal hematopoietic
tissue. It is an immunogenic protein, and an extensively
studied vaccine candidate [243]. Peptide and DC
vaccines using survivin alone or in combination with
other TAA are in development [244] as are survivin-
specific CTLs [245].
Chemotherapy approaches
Data are limited regarding the use of chemother-
apy for CLL relapse after alloHSCT. Many individ-
uals with CLL undergo allotransplant upon
identification of Flu-refractory disease, which predicts
poor response to salvage chemotherapy [246] as well as
to relapse after allogeneic transplantation [205]. How-
ever, response to salvage regimens for relapsed CLL
after allotransplant may be different, because ATM
and TP53 mutations, strongly associated with resis-
tance to Flu, alkylating agents and rituximab-based
regimens [247-250], do not predict for treatment
failure after allotransplantation [203,207,251,252]. It
is interesting to speculate whether clonal evolution of
CLL in response to GVL explains the anecdotal
experience of restored chemotherapy sensitivity after
allotransplant.
The only published reports on chemotherapy sal-
vage regimens for relapsed CLL after alloHSCT are
case series describing regimens given for cytoreduc-
tion prior to of DLI therapy. Sorror and colleagues
[211] reported no durable responses in 4 individuals
with CLL relapse using cytoreductive chemotherapy
(Flu/rituximab, CHOP, pentostatin/vincristine/pred-
nisone), andDLI. A later report describes 5 individuals
with CLL relapse who, after treatment with mAbs
combined with chemotherapy, were among a group
of patients who survived between 1 and 5 years after
treatment [203]. Delgado and colleagues [204] re-
ported on 6 patients with CLL relapse treated with
various regimens prior to DLI. There was 1 durable
complete response to CHOP, and 2 others had pro-
longed survival.
The effects of the specific agent or agents on en-
graftment, GVT and GVHD need to be factored in
to choice of CLL therapy. Purine analogs, including
Flu, are active in Flu-refractory disease when used in
combination with alkylating agents, particularly cyclo-
phosphamide (Cy); the combination has efficacy in
bulky or alemtuzumab-refractory disease [253,254].
But these regimens are myelosuppressive and result
in profound lymphocyte depletion, so it should
prompt consideration of donor stem-cell support.The addition of rituximab to Flu and Cy (FCR) im-
proves response rates and time to progression in the re-
fractory setting, although complete responses are
uncommon (overall response rate 5 59%; complete
response rate 5 5%) [255,256]. Pentostatin may be
less myelosuppressive than Flu, so may be preferred
for use after allotransplant; it also has activity in
combination with Cy for refractory CLL [257].
Here, too, the addition of rituximab improves efficacy,
with small, Phase II studies demonstrating response
rates that compare favorably with FCR [258].
Another treatment option for relapsed CLL is
bendamustine. Designed to have both alkylator and
purine antimetabolite properties, and only partial
cross-resistance with other alkylating agents in vitro
[259], bendamustine has activity against quiescent
and dividing cells, with activity unaffected by p53 or
ZAP-70 status [260]. However, increased hematologic
toxicity might be anticipated in treating CLL relapse
after allotransplant.
Immunotherapeutic agents
Some mAbs and immunomodulatory drugs have
activity against high-risk CLL. These agents may
work synergistically with standard salvage chemother-
apy regimens, with potential strengths and pitfalls in
their use after allotransplant. Alemtuzumab is an effec-
tive treatment of relapsed and refractory CLL. Few
patients have received alemtuzumab for treatment of
relapse after allotransplant, with no durable responses
reported [204]. Profound and long-lasting B and T cell
depletion, significant BM suppression, and risk of
serious infection limit its use in the post-alloHSCT
setting outside of the context of a clinical trial and/or
second transplant.
Rituximab treatment of CLL relapse is an appeal-
ing therapeutic option, as it is a commonly used tar-
geted agent, is familiar to transplant physicians, and
has a manageable toxicity profile. In treatment of re-
lapse after allotransplant, ‘‘single-agent’’ rituximab
may, in fact, work synergistically with an allogeneic im-
mune response, not only targeting residual CD201
CLLcells for ADCC-mediated cell death, but also sup-
porting donor cell-mediated antitumor cytotoxicity
through immunomodulatory effects (eg, effect of B
cell depletion on homeostatic cytokine levels). Com-
bining rituximab with DLI is a common and rational,
albeit inadequately studied strategy for treating
relapsed CLL, with direct CLL targeting and, poten-
tially, reduction of the significant risk of GVHD,
thereby minimizing the requirement for systemic
immune suppressive therapy [261].
Immunomodulatory drugs, such as lenalidomide,
may also have a role in treatment of relapse after trans-
plantation. This small molecule has a wide range of
immunomodulatory effects, includingT cell activation
through CD28, enhancement of NK cell cytotoxicity,
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as direct pro-apoptotic effects [262]. It is clinically
active in Flu-refractory CLL with overall response
rates of 30% achieved in patients with 11q- or 17p-de-
letions [263,264]. However, the drug should be used
cautiously as life-threatening tumor flare reaction
and tumor lysis syndrome have been reported [265],
and wide-ranging immunomodulatory effects may
have unanticipated, negative consequences after allo-
transplant.
Investigational targeted agents
Ofatumumab is a humanized anti-CD20 mAb that
binds to a different epitope than rituximab. It has in-
creased complement-dependent cytotoxicity against
B cells, redistributes CD20 into similar lipid raft
regions with a lower dissociation rate, and, in Phase I/II
studies, has shown impressive single-agent activity in re-
lapsed/refractory CLL [266,267]. Clinical investigation
in the treatment of allotransplant relapse, as a single
agent or combined with DLI, is warranted.
CD22 is often expressed on the surface of CLL
cells, even when CD20 is lost after mAb therapy.
CAT-8015 (HA22) is a recombinant anti-CD22 im-
munotoxin, with murine antihuman CD22 fused to
a truncated form of pseudomonas exotoxin, PE38. It
is in clinical evaluation for CD22-positive lymphoid
malignancies, including a pediatric study permitting
allotransplant recipients with tumor relapse (eg,
ALL, NHL). If activity is demonstrated in refractory
CLL, investigation in relapse after allotransplant
would be valuable [137,268].
The inhibitor of apoptosis (IAP) family of proteins
are being actively investigated in cancer therapy. Anti-
sense and small molecule therapeutics indirectly inhibit
IAP function via reduced mRNA expression of the tar-
get protein. In a phase III trial for relapsed/refractory
CLL, the addition of oblimersen, the antisense Bcl-2,
to Flu and Cy resulted in a higher complete response
rate (17% versus 7%), a longer response duration
[269], but is unfortunately no longer under develop-
ment. Survivin is another IAP, and may be a more
effective target than other IAP [270]. In addition to
antiapoptotic functions, it is a nodal protein linking
multiple pathways of cellular homeostasis (with regula-
tory activity in cell division, nonapoptotic cell death,
stress response, and tumor angiogenesis) [271].
YM155, a smallmolecule suppressor of survivin expres-
sion, is in clinical trials for CLL; whether it could in-
crease CLL susceptibility to DLI is worthy of
investigation. Lumiliximab is a chimeric macaque-
human anti-CD23 mAb. CD23 is a low-affinity IgE
receptor that is highly expressed on CLL cells. The
antibody primarily functions through induction of
apoptosis of CLL cells, through down-regulation of
BCL-2, BCL-XL, and XIAP, and through activation
of pro-apoptotic protein BAX and release of cyto-chrome C [272]. Addition of the antibody to the FCR
regimen appears to improve response rates in
relapsed/refractory CLL [273], investigation in con-
junction with DLI for relapse after alloHSCT may be
fruitful.
Flavopiridol, an investigational cyclin-dependent
kinase inhibitor, has shown promise against refractory
CLL in Phase I/II studies. Flavopiridol induces apo-
ptosis through a p53-independent pathway, and has
been shown to decrease expression of anti-apoptotic
proteins found in CLL, for example, MCL-1 [274],
and XIAP [275]. In Phase II study for relapsed CLL,
53% responded, including more than half of subjects
with 11q or 17p deletions, regardless of nodal size; me-
dian duration of response was 10-12 months. Serious
adverse events included severe tumor lysis syndrome
and IL-6-mediated cytokine release syndrome (CRS),
manifestations included fever, rash, and secretory
diarrhea. Although CRS was abrogated by the
addition of prophylactic dexamethasone, clinical fea-
tures would be difficult to distinguish from aGVHD
[276,277].Recommended Treatment Approaches for
Relapsed CLL after alloHSCT
In the absence of evidence-based therapeutic
options, the following approach takes into account the
behavior of CLL progression, status of donor
engraftment, and risk ofGVHD.As a first step, it is nec-
essary to define the behavior of the CLL in the context
of donor engraftment, immune suppression, and
GVHD. Figure 2 shows a conceptual framework for
treatment decisions that can be used for relapsed CLL
as well as other malignancies, and uses tumor behavior
and allograft function to determine whether the thera-
peutic goal is augmentation of the donor immune
response, cytoreductive tumor control, or both. As vir-
tually all established treatments for refractory CLLwill
also result in lymphocyte depletion, there may be the
additional effect of providing in vivo cytokine (eg, IL-
7 and IL-15) support for donor lymphocyte activation
and expansion. General approaches may include the
following.
Early relapse
Evaluation should include assessment of BM and
PB chimerism, and a complete staging evaluation to
determine sites of disease. The following consider-
ations influence specific treatment strategies.
CLL progression following an initial response to
the preparative regimen indicates inadequate GVT,
potentially because of persistent mixed chimerism,
a weak or blunted GVT, or lack of GVT. Treatment
goals are to control tumor and boost GVT, and
depend on pace of progression. Absent aGVHD, for
indolent progression it would be reasonable to try
Figure 2. Conceptual framework for treatment decisions for patients
with relapsed CLL after alloHSCT.
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ing to the addition of a targeted agent (eg, rituximab)
or retrial of the last active chemotherapy regimen for
more rapidly progressing disease.
In chemotherapy-refractory CLL, with progres-
sion through the preparative regimen, it may not be
possible to determine whether there is any GVT activ-
ity likely, and poses an extremely difficult treatment
challenge. If an untried regimen is available, it would
be reasonable to consider a trial with mobilized DLI
support.
In the case of CLL persistence upon establishment
of full donor chimerism, subclinical GVT may be
present. Absent clear progression, it would be reason-
able to consider watchful waiting, employing WIS
and/or DLI if no response is observed at subsequent
restaging, with addition of rituximab if there is evi-
dence of indolent progression.
In CLL progression following treatment of
GVHD, a blunted GVT response can be suspected.
There are no established treatment approaches that
permit GVT in this setting, and treatment goals are
to control tumor with minimal additional toxicity.
Reasonable alternatives include local irradiation, ritux-
imab, and single-agent therapy, depending on sites of
disease. The safety of intensive regimens, vis-a`-vis
GVHD and allograft function, has not been estab-
lished, nor is there data to suggest long-term efficacy.
Alemtuzumab-containing salvage therapy cannot be
recommended outside of a clinical trial, given risk of
potentially irreversible immune suppression, particu-
larly in the setting of active GVHD and contraindica-
tion to DLI. Consideration for investigational
therapies should always be considered.Late relapse
Evaluation should include assessment of BM and
PB chimerism, a complete staging evaluation to deter-
mine sites of disease, and a biopsy of active disease to
determine histology and/or chimerism, that is, to
rule out transformation, posttransplant lymphoproli-
ferative disease, donor CLL (consider in very late
BM relapse and/or family history of lymphoid malig-
nancies). The following considerations influence spe-
cific treatment strategies:
Late nodal relapse in the absence of BM involve-
ment may reflect transformation to more aggressive
tumor. Treatment goals are to control tumor and
boost allograft function, and consideration of a highly
active salvage regimen with stem-cell mobilized DLI
support is reasonable.
Recurrence of CLL may reflect waning GVT po-
tency, plausible causes include CLL immune escape,
with outgrowth of allo-resistant clones, and/or
‘‘burn-out’’ of the donor immune response. Treatment
goals are to reestablish disease sensitivity and/or
potency of GVT effects. In an indolent recurrence, it
would be reasonable to consider a trial of immune sup-
pression withdrawal, if possible, followed by a DLI
with or without rituximab. In more aggressive recur-
rences, it would be reasonable to consider the use of
salvage chemotherapy with DLI, even if the patient
has been refractory in the past. The recurrent CLL
may have lost resistance, and the lymphoid depleting
effects of the regimenmay support subsequent reestab-
lishment of GVT.
Very late recurrence of CLL and/or late recurrence
in BM only should prompt consideration of a donor-
derived CLL, particularly in sibling-donor allograft re-
cipients with a family history of lymphoid malignancies.
Given the increasing prevalence of MBL with age
greater than 50 years, even absent a family history,
very late BM relapse in patients whose donor was
more than 50 years old could represent a transferred
CLL. It would be reasonable to manage donor-
derived CLL according to standard guidelines for de
novo CLL, with treatment goals determined by disease
stage and behavior. Donor lymphocytes or other GVT-
based strategies to strengthen GVT would not have
a role in treatment.
Late CLL progression in the context of cGVHD
treatment may reflect blunted GVT activity. Treat-
ment goals are to control tumor with minimal addi-
tional toxicity. Reasonable alternatives include local
irradiation, and low-intensity chemotherapy, depend-
ing on sites of disease. Consideration of the addition
of rituximab is warranted, as there are preliminary
data to suggest that its use may help control cGVHD
[278,279]. Investigational strategies to increase the
tumor specificity of the donor immune response
would be attractive clinical trials. As with early
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containing regimens is theoretically attractive, with
potential for controlling CLL and GVHD, the poten-
tial for irreversible immunodeficiency in this patient
population is significant.
Conclusions on the Treatment of Relapsed CLL
after alloHSCT
There is no single standard of care for manage-
ment of CLL relapse after alloHSCT. Given the com-
plexity and heterogeneity of patients, donors, and
allograft function, treatment approaches will need to
be individualized, targeting specific relapse factors. Al-
though standard regimens may have a role in DLI
treatment of CLL relapse, even in previously refrac-
tory patients, clinical trials are needed to determine
the safety and efficacy of standard treatment regimens,
with and without additional donor lymphocytes, as
both individual patient responses and population pro-
files may be quite different after allotransplant. Inves-
tigation of novel approaches are needed as well, and
allotransplant recipients with persistent CLL should
be included in trials assessing efficacy of approved or
investigational agents in which immunomodulatory
effects may boost GVT responses.MM
Summary of Current Status
Compared with other treatment modalities in
multiple myeloma, alloHSCT induces the highest
rate of clinical complete and molecular remission
[280,281]; however, this results in long-term freedom
from disease in only about 30% to 40% of the patients
[280-284]. The introduction of RIC regimens has
lowered the TRM [285], and allows for more patients
to undergo transplantation, but the relapse rate is
considerably high exceeding nearly 50% at 3 years.
The incidence of relapse in patients with MM after
alloHSCT is higher than in other hematologic dis-
eases. Some investigators report a high incidence of ex-
tramedullary relapse, which does not influence efficacy
of salvage therapy [286,287]. However, the majority of
patients do not achieve CR (defined as negative
immunofixation) after allografting. Therefore, in thisTable 7. Salvage Therapies after Allogeneic Hematopoietic Stem C
ORR
1. Donor lymphocyte infusion (DLI) 40%-67%
2. CD8-depleted DLI 71%
3. Thalidomide 29%-83%
4. Lenalidomide 66%
5. Bortezomib 80%-100%
7. Thalidomide plus DLI 67%
9. HA-1 specific T cells
ORR indicates overall response rate; CR, complete remission; n.e., not evaluasection treatment options are discussed for both
relapse from CR as well as for persistent and
progressive disease in non-CR patients after alloHSCT.Treatment Options for Relapsed Multiple
Myeloma after alloHSCT (Table 7)
DLI
In MM, most reports using DLI are for relapse
[288-294], and there are few reports about
prophylactic DLI [295-297]. Response rates between
40% and 67% are reported, but in some studies
additional chemotherapy or interferon-a were given
[290,291]. Not all responses were durable. Nearly
30% of the patients achieved CR, and response to
DLI was correlated with occurrence and severity of
GVHD. The incidence of aGVHD ranges between
52% and 56% and of cGVHD between 26% and 44%.
DLI given after RIC in a dose-escalating fashion
resulted in less aGVHD and cGVHD [295,297]. In
a survey of 8 European transplant centers, the effect
of DLI after RIC was investigated in patients with
relapsed (n 5 48) or persistent disease (n 5 15) after
alloHSCT. Nineteen percent of the patients achieved
PR, and 19% achieved CR [298]. The median time to
progression was 7 months for patients with PR and
28 months for patients who achieved CR.
Selected T cell infusions
To reduce the risk of GVHD after DLI, CD81
T cells can be depleted either by positive CD41
T cell enrichment or by CD81 T cell depletion.
CD81T cell depleted DLI were investigated in 14 pa-
tients in CR (n5 3) or persistent disease (n5 11) after
M T cell-depleted alloHSCT as a method to induce
a graft-versus-myeloma effect, which may have been
compromised by the T cell depletion at time of trans-
plant. Six of the 10 patients with measurable disease
experiencedCR, but these remissions were not durable
in themajority of patients. aGVHD (grade II—IV) was
seen in 50% of the patients [296], which was similar to
reports after unmodifiedDLI.More recently depletion
of alloreactiveT cells is under investigation, but nodata
for this approach asDLI for relapsedmyeloma patients
are available [299].ell Transplantation for Patients with Multiple Myeloma
CR Overall Survival
19%-30% med. 23-23.6 mo
43% 2 year: 55%
0%-22% 3 year: 25%
8%-23% med. 19.9 mo
29%-30% 3 year: 50%
22% 2 year: 100%
1/1 CR
ble.
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Because the immunomodulatory drugs (IMIDs)
thalidomide and lenalidomide induce enhanced T
cell activation and NK-cell activation [300], combina-
tion therapy could be a useful track to enhance the
graft-versus-myeloma effect after alloHSCT. To en-
hance the antimyeloma effect of DLI after allografting,
low-dose thalidomide (100 mg) in combination with
DLI was investigated. The overall response rate was
67%, with 22% CR. Interestingly, no grade II 5 IV
aGVHD was seen, and only a small minority devel-
oped limited cGVHD [301].Novel agents
Because of the aforementioned immunologic ef-
fect of thalidomide and lenalidomide on T and NK
cells, these agents might be of special interest in
patients with MM after alloHSCT. Thalidomide as
single agent at a median dose of 200 mg (range: 50-
600 mg) has been investigated in 31 patients as salvage
therapy after progression following alloHSCT. Be-
cause of toxicity the drug was been discontinued in
19% of the patients. Twenty-nine percent of the pa-
tients achieved an objective response (PR and very
good partial remission [VGPR]). In 5 patients mild
GVHD developed after thalidomide treatment [302].
Lenalidomide has been investigated in 24 heavily
pretreated myeloma patients with relapse after al-
loHSCT at a dose of 15 or 25 mg. Major side effects
were leukopenia (grade 3-4: 25%), and thrombocyto-
penia (grade 3: 17%). Nonhematologic toxicity con-
sisted of muscle cramps (n 5 9), fatigue (n 5 5), and
constipation (n 5 2). Mild grade I-II GVHD was
seen in 3 patients. Response was achieved in 66% of
patients (CR 5 8%, VGPR 5 8%, PR 5 50%, and
SD5 13%). The median time to progression and sur-
vival was 9.7 and 19.9 months, respectively. Immune
monitoring after lenalidomide showed significant in-
crease of activated NK (NKp441) and T (HLA-
DR1) cells as well as Treg cells (CD41, CD251,
CD127lo), supporting an immunomodulating anti-
myeloma effect of lenalidomide [303]. A Dutch study
reported on the activity of lenalidomide after allograft-
ing [304]. This study showed high activity of lenalido-
mide with and without dexamethasone in patients with
MM after failure to alloHSCT including a CR rate of
23%. In this study, an increase of Treg cells after lena-
lidomide treatment was observed, but also 5 of 13 pa-
tients developed aGVHD between 2 and 13 days after
start of treatment. However, patients treated with le-
nalidomide in combination with dexamethasone did
not develop any GVHD.
Other drugs such as the proteasome-inhibitor
bortezomibmight have amajor role after alloHSCT be-
cause it was shown in preclinicalmodels that proteasome
inhibition inhibits T cell proliferation and aGVHD bydepleting alloreactive T cells and retaining the GVT
effect [305-307]. Bortezomib as salvage therapy in
myeloma patients who relapsed after reduced-intensity
alloHSCT has been investigated in 37 patients. Major
side effects were grade 1-2 peripheral neuropathy
(35%), mild thrombocytopenia (24%), and fatigue
(19%),whereas therewasnoworseningofGVHDsymp-
toms. Seventy-three percent of the patients achieved an
objective response and the estimate of OS was 65% at
18 months, which was significantly higher (P5 .002) in
patients achieving an objective response [308].
In a further study, a median of 2 cycles of bortezo-
mib was investigated as posttransplant treatment to
enhance remission status. Grade III/IV toxicity was
seen for thrombocytopenia (50%), leukopenia (17%),
or neuropathy (17%), which was more often seen in
patients treated concomitantly with cyclosporine
(P 5 .06). The median circulating CD31 T cells
decreased during treatment from 550 mL to 438 mL
(P 5 .03), resulting in herpes zoster infection in 3 pa-
tients (17%). The regimen was very effective inducing
complete or PR in 30% and 50%, respectively [309].
Overall, the novel agents are very effective as sal-
vage therapy and a European survey showed that
even in patients refractory to DLI, salvage treatment
with thalidomide or bortezomib can induce CR or
PR in 83% of the cases [310]. Furthermore, it seems
that these new drugs with immunomodulatory proper-
ties can induce graft-versus-myeloma effect without
increasing risk of GVHD.
Second allogeneic transplant
A second allogeneic transplantation as treatment
for relapsing patients has been described for myeloge-
nous malignancies, but no data have been reported for
myeloma patients.Other investigational options-targeted therapy
Interferon-a alone induced a CR without GVHD
in 4 of 5 patients after allograft, but because inter-
feron-a was given rather early at a median of 126 days
after transplantation, the contribution of interferon
to achieve CR remains unclear [311]. The major issue
for further improvement of immunologically based
strategies post-allotransplant lies in the separation of
the graft-versus-myeloma effect from the graft-
versus-host reaction,whichwould allow amore specific
tumor targetingwithout orwith a lesser risk ofGVHD.
Potential candidate targets for amore specificT cell re-
sponse are miHags such as HA-1. More recently, HA-
1-specific T cells could be generated and induced CR
in a patient with relapsed MM after alloHSCT [9]. A
potential target for tumor-specific donor-T cell re-
sponse is the myeloma-specific idiotypic determinant
of immunoglobulin-variable region, which has been
used to immunize the donor prior to alloHSCT in
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[312]. Two of 5 patients remained disease free after al-
lografting for 7 and 8 years, respectively, whereas 1 pa-
tient died of renal failure 5 years after transplantation.
In all patients immunoglobulin-specificTcell response
was seen and persisted for 18 months [313]. Another
potential target is cancer-testis (CT)-antigens, espe-
cially MAGEC2 or MAGEA3, which are expressed in
more than 55% of myeloma cells [314]. A donor vacci-
nation with MAGEA3 induced T cell response in the
donor as well as in the recipient after alloHSCT
[315]. However, frequent antibody responses against
CT antigen were observed after allografting without
donor vaccination [315].This antibody response corre-
lated with specific CD41 and CD81 T cell response.
This responsewas neither detectable in pretransplanta-
tion samples in the patients nor in the donors, suggest-
ing that CT antigens might represent a natural target
for graft-versus-myeloma effects. KIR-ligand-donor/
recipient-mismatch transplantation may be protective
against relapse, suggesting a potential role of alloreac-
tive NK-cells after allografting to treat relapse [316].
Other potential targets have been identified by analyz-
ing humoral responses in patients who achieve CRs
after DLI. One B cell antigen was B cell maturation
antigen (BCMA), a transmembrane receptor of the
tumor necrosis factor superfamily. In vitro analysis
demonstrated serum was able to induce complement-
mediated lysis and antibody-dependent cellular cyto-
toxicity of transfected cells as well as primary myeloma
cells expressing BCMA. Perhaps either antibodies with
specificity to targets such as this, or antibodies inducing
stronger responses in vivo to these targets or similar
targets may enhance the response to DLI [317].FutureDirections for the Treatment of Relapsed
MM after alloHSCT
Although the data demonstrate the presence of
a strong graft-versus-myeloma effect, many challenges
remain in addressing relapse after transplant in patients
with myeloma. The low complete response rate and
durability of responses after DLI suggest that our cur-
rent approaches are not sufficient. However, in some
patients who experienced a CR after DLI, long-term
survival can be achieved. Becausemost of the responses
are associatedwith occurrence ofGVHD,major efforts
should bemade to separate graft-versus-myeloma from
GVHD. Efforts to enhance responses may include
earlier use of DLI as well as perhaps sequential DLI
to maintain remissions in patients who respond with-
out developing GVHD. More recently available novel
agents induce similar response and survival rates
after alloHSCT than after relapse to an autograft or
to conventional therapies. Because of the immune-
modulating properties of the novel agents, combina-
tion with DLI is an attractive concept, and doses andtiming of both DLI and the novel agents need to be
explored. Finally, targeted cellular therapies may
improve responses as well as limit toxicity.SUMMARY
When considering treatment options for patients
who relapse after alloHSCT, several issues transcend
disease specificity. Other than the successes docu-
mented years ago using DLI for relapsed CML, there
is remarkably limited data on the use of DLI and non-
DLI therapies in other clinical situations. The lack of
data regarding treatment options and outcomes results
from many factors. Patients who relapse after trans-
plant are an extremely heterogeneous group. Some
may be quite ill andmay still be suffering frommorbid-
ities of transplant. Some may have had, or still have,
active GVHD and may or may not be on immune sup-
pression. Furthermore, the biology and responsiveness
of diseases that relapse rapidly after transplant are
likely very different than diseases that relapse later
after transplant. Treatment options and responses
are likely to be very different in these different patient
groups. This heterogeneity leads to enormous selec-
tion bias that can be compounded by reporting bias
where only the best and most promising results are
disseminated. Treatment options are also affected by
prior therapies and the previous failed transplant.
HLA-identical sibling transplants usually have access
to their previous donor. Cord blood recipients never
do, and DLI from an unrelated donor may be delayed
andmay or may not have higher risks. Therefore, there
is obviously no single standard approach to treating
relapse after alloHSCT.
It is unknown whether GVT induction for relapse
is a generalized allogeneic effect or has disease specific
targets. It is also unknown whether GVT induction
can be effectively separated from GVHD. It is still un-
clear whether there is a relationship between cell dose
and toxicity with DLI, and it is not known whether
there is a dose-response effect, or rather a minimal
threshold dose that must be achieved before antitumor
responses occur. Whether these dose effects might be
disease or disease-state specific is also unanswered.
There are clinical situations where responses to
DLI consistently have been poor andmaneuvers to im-
prove GVT induction need to be tested rapidly and
comprehensively. It is imperative to study and under-
stand mechanisms leading to relapse to develop and
use the proper strategy for a specific disease or specific
patient. For instance, in some cases, relapse of acute
leukemia or MDS after haploidentical alloHSCT has
been associated with loss of recipient-specific HLA ex-
pression. In these cases, conventional DLI would not
be expected to be effective, assuming HLA class I
and II antigens are necessary targets for GVT
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with ineffective T cell activation, either because of
tumor suppression, lack of costimulatory molecules,
or T cell-associated defects, ex vivo activation of donor
T cells prior to infusion may restore GVT activity.
There are also clear instances where second transplant
is a reasonable and effective option, and considerations
of the proper disease and patient population, condi-
tioning regimen intensity, and donor choice for second
alloHSCT need to be revisited.
Alternatives to cellular therapies to treat relapse
should not be neglected. It has been difficult to use
and study conventional and novel agents because the
dosing regimens and toxicity profiles may be very
different in posttransplant patients. Outcomes likely
depend on prior therapy, disease activity, timing of
relapse, GVHD, and other coincident toxicities, as
well as many other factors. Furthermore, anecdotal
observations suggest an interaction between ongoing
GVT effects and various other therapeutic interven-
tions. Well-designed clinical trials in specific diseases
are going to be necessary to test the activity and role
for these therapies, particularly in situations where
cellular therapies have been ineffective. Measurements
of immunologic effects in addition to disease outcomes
will be needed to make progress in managing disease
relapse with conventional and biologic therapies. In
addition, we must overcome the general reluctance of
study sponsors and investigators to include prior trans-
plant recipients on trials studying promising new
therapies; these often unsubstantiated exclusions may
deprive patients of potential major benefits and slow
progress in developing relapse therapies.
A number of strategies deserve careful study and
might include preparation and pretreatment of the
patient to either induce a minimal disease state or
perhaps alter the malignant cells and environment
to enhance T cell recognition and GVT activity. Al-
ternatively, manipulation of the donor cell product
through selection, activation, or targeting may en-
hance GVT activity. Studying the role of other cellu-
lar effectors such as NK cells and dendritic cells to
enhance GVT will also be important. In many cases,
a combination of these strategies may be required for
maximal effect. Combining immunologic approaches
with novel chemotherapy or biologic therapies in
a multimodality approach may ultimately be required.
Given the multitude of confounding issues, and the
relatively small numbers of patients, the committee
on Treatment of Relapse for this Workshop was
unanimous in acknowledging the need for well-
designed international cooperative trials to rapidly
test and disseminate the best strategies for relapse
treatment after transplant. Information gathered in
the relapse setting could, at least in theory, provide
crucial pathophysiologic information that may ulti-
mately improve treatments.Despite all the uncertainties, there is no doubt that
novel biologic agents and allogeneic immunotherapy
have the ability to be very potent and durable antican-
cer therapies. Detailed study of the current role for
DLI, and exploring new applications of cellular and
other biologic therapy continues to hold great promise
for the very dire clinical scenario of relapsed disease
after alloHSCT.ACKNOWLEDGMENTS
Financial disclosure: All authors participated in the
NCI sponsored workshop that forms the basis of this
report and contributed to and reviewed the final man-
uscript. The major authors of the individual sections
include CML (J.H.F.F., J.H.A.), AML (M.dL., E.E.,
J.L.), ALL (J.M.R., A.W.), NHL (K.vB., D.M.), HL
(K.P., D.L.P.), CLL (J.L., N.H.), and MM (N.K.,
E.A.).REFERENCES
1. CairoMS, Jordan CT,Maley CC, et al. NCI first international
workshop on the biology, prevention, and treatment of relapse
after allogeneic hematopoietic stem cell transplantation: report
from the committee on the biological considerations of hema-
tological relapse following allogeneic stem cell transplantation
unrelated to graft-versus-tumor effects: state of the science.Biol
Blood Marrow Transplant. 2010;16:709-728.
2. HorowitzMM,Gale RP, Sondel PM, et al. Graft-versus-leuke-
mia reactions after bone marrow transplantation. Blood. 1990;
75:555-562.
3. Kolb HJ, Mittermu¨ller J, Clemm C, et al. Donor leukocyte
transfusions for treatment of recurrent chronic myelogenous
leukemia in marrow transplant patients. Blood. 1990;76:
2462-2465.
4. Collins RH Jr., ShpilbergO,DrobyskiWR, et al. Donor leuko-
cyte infusions in 140 patients with relapsedmalignancy after al-
logeneic bone marrow transplantation. J Clin Oncol. 1997;15:
433-444.
5. PorterDL,RothMS,McGarigleC, Ferrara JLM,Antin JH. In-
duction of graft-versus-host disease as immunotherapy for re-
lapsed chronic myeloid leukemia. N Engl J Med. 1994;330:
100-106.
6. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete re-
mission of accelerated phase chronic myeloid leukemia by
treatment with leukemia-reactive cytotoxic T lymphocytes.
Blood. 1999;94:1201-1208.
7. vondemBornePA, vanLuxemburg-Heijs SA,HeemskerkMH,
et al.Molecular persistence of chronicmyeloid leukemia caused
by donor T cells specific for lineage-restricted maturation anti-
gens not recognizing immature progenitor-cells. Leukemia.
2006;20:1040-1046.
8. Falkenburg JH, van de Corp, Marijt EW, Willemze R. Minor
histocompatibility antigens in human stem cell transplantation.
Exp Hematol. 2003;31:743-751.
9. MarijtWA,HeemskerkMH,Kloosterboer FM, et al. Hemato-
poiesis-restricted minor histocompatibility antigens HA-1- or
HA-2-specific T cells can induce complete remissions of re-
lapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742-2747.
10. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to
H-Y minor histocompatibility antigens correlate with chronic
graft-versus-host disease and disease remission. Blood. 2005;
105:2973-2978.
Biol Blood Marrow Transplant 16:1467-1503, 2010 1495NCI First International Workshop on alloHSCT11. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive
immunotherapy evaluating escalating doses of donor leuko-
cytes for relapse of chronic myeloid leukemia after bone mar-
row transplantation: separation of graft-versus-leukemia
responses from graft-versus-host disease. Blood. 1995;86:
1261-1268.
12. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte in-
fusion for relapsed chronic myelogenous leukemia: prognostic
relevance of the initial cell dose. Blood. 2002;100:397-405.
13. Chalandon Y, Passweg JR, Schmid C, et al. Outcome of
patients developing GVHD after DLI given to treat CML re-
lapse: a study by the Chronic Leukemia Working Party of the
EBMT. Bone Marrow Transplant. 2010;45:558-564.
14. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses
following donor lymphocyte infusions for patients who relapse
after allogeneic stem cell transplantation for chronic myeloid
leukemia. Blood. 2000;96:2712-2716.
15. PorterDL,CollinsRHJr.,HardyC, et al.Treatment of relap sed
leukemia after unrelated donor marrow transplantation with
unrelated donor leukocyte infusions. Blood. 2000;95:1214-1221.
16. Cunningham I. Extramedullary sites of leukemia relapse after
transplant. Leuk Lymphoma. 2006;47:1754-1767.
17. Ocheni S, Iwanski GB, Schafhausen P, et al. Characterisation
of extramedullary relapse in patients with chronic myeloid leu-
kemia in advanced disease after allogeneic stem cell transplan-
tation. Leuk Lymphoma. 2009;50:551-558.
18. Collins RH Jr., Rogers ZR, Bennett M, Kumar V, Nikein A,
Fay JW. Hematologic relapse of chronic myelogenous leukemia
following allogeneic bone marrow transplantation: apparent
graft-versus-leukemia effect following abrupt discontinuation
of immunosuppression. Bone Marrow Transplant. 1992;10:
391-395.
19. Imado T, Iwasaki T, Kuroiwa T, Sano H, Hara H. Effect of
FK506 on donor T-cell functions that are responsible for
graft-versus-host disease and graft-versus-leukemia effect.
Transplant. 2004;77:391-398.
20. Lee SJ, KukrejaM,WangT, et al. Impact of prior imatinibme-
sylate on the outcome of hematopoietic cell transplantation for
chronic myeloid leukemia. Blood. 2008;112:3500-3507.
21. Higano CS, Chielens D, Raskind W, et al. Use of alpha-2a-
interferon to treat cytogenetic relapse of chronic myeloid leu-
kemia after marrow transplantation. Blood. 1997;90:2549-2554.
22. Posthuma EF, Marijt EW, Barge RM, et al. Alpha-interferon
with very-low-dose donor lymphocyte infusion for hematologic
or cytogenetic relapse of chronic myeloid leukemia induces
rapid and durable complete remissions and is associated with
acceptable graft-versus-host disease. Biol Blood Marrow Trans-
plant. 2004;10:204-212.
23. Klyuchnikov E, Kroger N, Brummendorf TH,Wiedemann B,
Zander AR, Bacher U. Current status and perspectives of
tyrosine kinase inhibitor treatment in the posttransplant period
in patients with chronic myelogenous leukemia (CML). Biol
Blood Marrow Transplant. 2010;16:301-310.
24. Wright MP, Shepherd JD, Barnett MJ, et al. Response to tyro-
sine kinase inhibitor therapy in patients with chronic myeloge-
nous leukemia relapsing in chronic and advanced phase
following allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2010;16:639-646.
25. Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion fol-
lowed by donor lymphocyte infusion (DLI) causes significantly
more acute graft-versus-host disease than DLI alone. Blood.
2007;110:2761-2763.
26. Kolb HJ. Graft-versus-leukemia effects of transplantation and
donor lymphocytes. Blood. 2008;112:4371-4383.
27. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed
leukemia after allogeneic hematopoietic cell transplantation
with T cells specific for minor histocompatibility antigens.
Blood. 2010;115:3869-3878.
28. Molldrem JJ, Komanduri K, Wieder E. Overexpressed differ-
entiation antigens as targets of graft-versus-leukemia reactions.
Curr Opin Hematol. 2002;9:503-508.29. Brauer KM,Werth D, von Schwarzenberg K, et al. BCR-ABL
activity is critical for the immunogenicity of chronic myeloge-
nous leukemia cells. Cancer Res. 2007;67:5489-5497.
30. Quintarelli C, Dotti G, De Angelis B, et al. Cytotoxic T lym-
phocytes directed to the preferentially expressed antigen of
melanoma (PRAME) target chronic myeloid leukemia. Blood.
2008;112:1876-1885.
31. Sillaber C, HerrmannH, Bennett K, et al. Immunosuppression
and atypical infections in CML patients treated with dasatinib
at 140 mg daily. Eur J Clin Invest. 2009;39:1098-1109.
32. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell
receptor-mediated T-cell proliferation and activation in
a dose-dependent manner. Blood. 2005;105:2473-2479.
33. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA
in leukemia after stem-cell transplantation.NEngl JMed. 2009;
361:478-488.
34. Wu CJ, Biernacki M, Kutok JL, et al. Graft-versus-leukemia
target antigens in chronic myelogenous leukemia are expressed
on myeloid progenitor cells. Clin Cancer Res. 2005;11:
4504-4511.
35. Jedema I, van Dreunen L, Willemze R, Falkenburg JHF.
Treatment with tyrosine kinase inhibitors may impair the
potential curative effect of allogeneic stem cell transplantation.
Blood (ASH Annu Meet Abstr). 2009;114:857.
36. Nagler A, Volchek Y, Yerushalmi R, et al. Nilotinib treatment
post-allogeneic stemcell transplantation (alloSCT) in advanced
(.CP1) chronic myeloid leukemia (CML) and Ph1 acute
lymphoblastic leukemia (ALL). Blood (ASH Annu Meet Abstr).
2009;114:1176.
37. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of
defined doses of CD4(1) donor lymphocytes for treatment of
relapse after allogeneic bone marrow transplant. Blood. 1998;
91:3671-3680.
38. Porter DL, Antin JH. Donor leukocyte infusions in myeloid
malignancies: new strategies. Best Pract Res Clin Haematol.
2006;19:737-755.
39. Ho VT, VannemanM, KimH, et al. Biologic activity of irradi-
ated, autologous, GM-CSF-secreting leukemia cell vaccines
early after allogeneic stem cell transplantation. Proc Natl Acad
Sci USA. 2009;106:15825-15830.
40. Kroger N, Bacher U, Bader P, et al. NCI First International
Workshop on the biology, prevention and treatment of re-
lapse after allogeneic hematopoietic stem cell transplantation:
report from the Committee on Disease-Specific Methods and
Strategies for Monitoring Relapse Following Allogeneic Stem
Cell Transplantation. Part I: methods, acute leukemias and
myelodysplastic syndromes. Biol Blood Marrow Transplant.
2010.
41. Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assess-
ment of WT1 gene expression after allogeneic stem cell trans-
plantation is a useful tool for monitoring minimal residual
disease in acute myeloid leukemia. Eur J Haematol. 2009;82:
61-68.
42. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR,
Kroger N. Quantitative monitoring of NPM1 mutations
provides a valid minimal residual disease parameter following
allogeneic stem cell transplantation. Exp Hematol. 2009;37:
135-142.
43. Shaw BE, Russell NH. Treatment options for the management
of acute leukaemia relapsing following an allogeneic transplant.
Bone Marrow Transplant. 2008;41:495-503.
44. OdomLF, August CS, Githens JH, et al. Remission of relapsed
leukemia during a graft-versus-host reaction: a ‘‘graft-versus-
leukemia’’ reaction in man? Lancet. 1978;ii:537-539.
45. Oran B, Giralt S, Couriel D, et al. Treatment of AML and
MDS relapsing after reduced-intensity conditioning and
allogeneic hematopoietic stem cell transplantation. Leukemia.
2007;21:2540-2544.
46. Loren AW, Porter DL. Donor leukocyte infusions for the
treatment of relapsed acute leukemia after allogeneic stem
cell transplantation. BoneMarrow Transplant. 2008;41:483-493.
1496 Biol Blood Marrow Transplant 16:1467-1503, 2010D. L. Porter et al.47. van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine-
melphalan conditioning for AML and MDS: alemtuzumab re-
duces acute and chronic GVHD without affecting long-term
outcomes. Biol Blood Marrow Transplant. 2009;15:610-617.
48. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-
leukemia effect of donor lymphocyte transfusions in marrow
grafted patients. European Group for Blood and Marrow
Transplantation Working Party Chronic Leukemia. Blood.
1995;86:2041-2050.
49. Levine JE, BraunT, Penza SL, et al. Prospective trial of chemo-
therapy and donor leukocyte infusions for relapse of advanced
myeloid malignancies after allogeneic stem-cell transplanta-
tion. J Clin Oncol. 2002;20:405-412.
50. Porter DL. Donor leukocyte infusions in acute myelogenous
leukemia. Leukemia. 2003;17:1035-1037.
51. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte in-
fusion in the treatment of first hematological relapse after allo-
geneic stem-cell transplantation in adults with acute myeloid
leukemia: a retrospective risk factors analysis and comparison
with other strategies by the EBMT Acute Leukemia Working
Party. J Clin Oncol. 2007;25:4938-4945.
52. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, HanW. Donor
lymphocyte infusion for the treatment of leukemia relapse after
HLA-mismatched/haploidentical T-cell-replete hematopoi-
etic stem cell transplantation. Haematology. 2007;92:414-417.
53. Rizzieri DA, Dev P, Long GD, et al. Response and toxicity
of donor lymphocyte infusions following T-cell depleted
non-myeloablative allogeneic hematopoietic SCT from 3-6/6
HLA matched donors. Bone Marrow Transplant. 2009;43:
327-333.
54. Levine JE, Barrett AJ, Zhang MJ, et al. Donor leukocyte infu-
sions to treat hematologic malignancy relapse following
allo-SCT in a pediatric population. Bone Marrow Transplant.
2008;42:201-205.
55. Flowers ME, Leisenring W, Beach K, et al. Granulocyte
colony-stimulating factor given to donors before apheresis
does not prevent aplasia in patients treated with donor leuko-
cyte infusion for recurrent chronic myeloid leukemia after
bone marrow transplantation. Biol Blood Marrow Transplant.
2000;6:321-326.
56. Alyea EP, Canning C, Neuberg D, et al. CD81 cell depletion
of donor lymphocyte infusions using cd8 monoclonal
antibody-coated high-density microparticles (CD8-HDM)
after allogeneic hematopoietic stem cell transplantation: a pilot
study. Bone Marrow Transplant. 2004;34:123-128.
57. Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of
CD81 T-cell depletion in the prevention of graft-versus-host
disease associated with donor lymphocyte infusion. Biol Blood
Marrow Transplant. 2002;8:625-632.
58. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lympho-
cyte infusion as treatment for relapsed chronic myelogenous
leukemia after allogeneic bone marrow transplantation. Blood.
1995;86:4337-4343.
59. Mielcarek M, Storer BE, Flower MED, Storb R, Sandmaier B,
Martin PJ. Outcomes among patients with recurrent high-risk
hematologic malignancies after allogeneic hematopoietic cell
transplantation. Biol Blood Marrow Transplant. 2007;13:
1160-1168.
60. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute
leukemia after marrow transplantation: natural history and
results of subsequent therapy. J Clin Oncol. 1989;7:50-57.
61. Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute
myeloid leukemia after allogeneic bone marrow transplanta-
tion with chemotherapy followed by G-CSF-primed donor
leukocyte infusion: a high incidence of isolated extramedullary
relapse. Leukemia. 2004;18:1789-1797.
62. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine
after allogeneic stem cell transplantation for acute leukemia.
Cancer. 2009;115:1899-1905.
63. Lubbert M, Bertz H, Ruter B, et al. Non-intensive treatment
with low-dose 5-aza-20-deoxycytidine (DAC) prior to alloge-neic blood SCT of older MDS/AML patients. Bone Marrow
Transplant. 2009;44:585-588.
64. Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-
dose treatment with 5-azacytidine followed by donor lympho-
cyte infusions in older patients with acute myeloid leukemia or
chronic myelomonocytic leukemia relapsed after allografting.
Bone Marrow Transplant. 2009;45:627-632.
65. De Padua SL, de Lima M, Kantarjian H, et al. Feasibility of
allo-SCT after hypomethylating therapy with decitabine for
myelodysplastic syndrome. Bone Marrow Transplant. 2009;43:
839-843.
66. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of
sorafenib in FLT3-ITD-positive acute myeloid leukemia:
sustained regression before and after allogeneic stem cell trans-
plantation. Blood. 2009;113:6567-6571.
67. Estey EH, Thall PF. New designs for phase 2 clinical trials.
Blood. 2003;102:442-448.
68. Arfons LM, Tomblyn M, Rocha V, Lazarus HM. Second he-
matopoietic stem cell transplantation in myeloid malignancies.
Curr Opin Hematol. 2009;16:112-123.
69. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant
for acute and chronic leukemia relapsing after first HLA-
identical sibling transplant. Bone Marrow Transplant. 2004;34:
721-727.
70. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor
natural killer cell alloreactivity in mismatched hematopoietic
transplants. Science. 2002;295:2097-2100.
71. Clausen J,Wolf D, Petzer AL, et al. Impact of natural killer cell
dose and donor killer-cell immunoglobulin-like receptor (KIR)
genotype on outcome following human leucocyte antigen-
identical haematopoietic stem cell transplantation. Clin Exp
Immunol. 2007;148:520-528.
72. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with
group B KIR haplotypes improve relapse-free survival after
unrelated hematopoietic cell transplantation for acute myelog-
enous leukemia. Blood. 2009;113:726-732.
73. Baron F, Petersdorf EW, Gooley T, et al. What is the role for
donor natural killer cells after nonmyeloablative conditioning?
Biol Blood Marrow Transplant. 2009;15:580-588.
74. McKenna DH Jr., Sumstad D, Bostrom N, et al. Good
manufacturing practices production of natural killer cells for
immunotherapy: a six-year single-institution experience.
Transfusion. 2007;47:520-528.
75. Lee KH, Lee JH, Choi SJ, et al. Bone marrow vs extramedul-
lary relapse of acute leukemia after allogeneic hematopoietic
cell transplantation: risk factors and clinical course. Bone
Marrow Transplant. 2003;32:835-842.
76. Nguyen K, Devidas M, Cheng SC, et al. Factors influencing
survival after relapse from acute lymphoblastic leukemia:
a Children’s Oncology Group study. Leukemia. 2008;22:
2142-2150.
77. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609
adults after relapse of acute lymphoblastic leukemia (ALL);
an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:
944-950.
78. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone
marrow transplantation in acute leukemia: results of a survey
by the European Cooperative Group for Blood and Marrow
Transplantation. J Clin Oncol. 2001;19:3675-3684.
79. Kishi K, Takahashi S, Gondo H, et al. Second allogeneic bone
marrow transplantation for post-transplant leukemia relapse:
results of a survey of 66 cases in 24 Japanese institutes. Bone
Marrow Transplant. 1997;19:461-466.
80. Michallet M, Tanguy ML, Socie G, et al. Second allogeneic
haematopoietic stem cell transplantation in relapsed acute
and chronic leukaemias for patients who underwent a first allo-
geneic bone marrow transplantation: a survey of the Societe
Francaise de Greffe de moelle (SFGM). Br J Haematol. 2000;
108:400-407.
81. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploi-
dentical hematopoietic stem cell transplantation in adults
Biol Blood Marrow Transplant 16:1467-1503, 2010 1497NCI First International Workshop on alloHSCTwith high-risk acute leukemia: a risk factor analysis of outcomes
for patients in remission at transplantation. Blood. 2008;112:
3574-3581.
82. Frassoni F, Barrett AJ, Gran˜ena A, et al. Relapse after alloge-
neic bonemarrow transplantation for acute leukaemia: a survey
by the E.B.M.T. of 117 cases. Br J Haematol. 1988;70:317-320.
83. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic ef-
fect of graft-versus-host disease in human recipients of alloge-
neic marrow grafts. N Engl J Med. 1979;300:1068-1073.
84. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow
transplants fromHLA-identical siblings as compared with che-
motherapy for children with acute lymphoblastic leukemia in
a second remission. N Engl J Med. 1994;331:1253-1258.
85. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic ther-
apy with hematopoietic stem cell transplantation in the therapy
of acute lymphoblastic leukemia in children: an evidence-based
review. Biol Blood Marrow Transplant. 2005;11:823-861.
86. Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA-
matched sibling transplantation or chemotherapy in children
with B-precursor acute lymphoblastic leukemia in a second
remission: a collaborative study of the Children’s Oncology
Group and the Center for International Blood and Marrow
Transplant Research. Blood. 2006;107:4961-4967.
87. Goldstone AH, Richards SM, LazarusHM, et al. In adults with
standard-risk acute lymphoblastic leukemia, the greatest bene-
fit is achieved from amatched sibling allogeneic transplantation
in first complete remission, and an autologous transplantation
is less effective than conventional consolidation/maintenance
chemotherapy in all patients: final results of the International
ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;
111:1827-1833.
88. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host
disease prophylaxis with low-dose cyclosporine-A reduces the
risk of relapse in children with acute leukemia given
HLA-identical sibling bone marrow transplantation: results
of a randomized trial. Blood. 2000;95:1572-1579.
89. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of
leukemia relapse with high-dose cyclosporine A after alloge-
neic marrow transplantation for acute leukemia. Blood. 1991;
77:1423-1428.
90. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute
lymphoblastic leukemia cells may induce T-cell anergy to
alloantigen. Blood. 1996;88:41-48.
91. Helg C, Starobinski M, JeannetM, Chapuis B. Donor lympho-
cyte infusion for the treatment of relapse after allogeneic hema-
topoietic stem cell transplantation. Leuk Lymphoma. 1998;29:
301-313.
92. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J,
Or R. Allogeneic cell therapy for relapsed leukemia after bone
marrow transplantation with donor peripheral blood lympho-
cytes. Exp Hematol. 1995;23:1553-1562.
93. Szer J, Grigg AP, Phillips GL, SheridanWP. Donor leucocyte
infusions after chemotherapy for patients relapsing with acute
leukaemia following allogeneic BMT. Bone Marrow Transplant.
1993;11:109-111.
94. Ferster A, Bujan W, Mouraux T, Devalck C, Heimann P,
Sariban E. Complete remission following donor leukocyte
infusion in ALL relapsing after haploidentical bone marrow
transplantation. Bone Marrow Transplant. 1994;14:331-332.
95. Atra A,Millar B, Shepherd V, et al. Donor lymphocyte infusion
for childhood acute lymphoblastic leukaemia relapsing after
bonemarrow transplantation. Br J Haematol. 1997;97:165-168.
96. RymesNL,Murray JA, Holmes JA. Abrupt cessation of immu-
nosuppression in a patient with persistent acute lymphoblastic
leukaemia following allogeneic transplantation. Clin Lab
Haematol. 1996;18:45-46.
97. AokiY,TakahashiS,OkamotoS,AsanoS.Graft-versus-leukemia
after secondallogeneic bonemarrow transplantation.Blood. 1994;
84:3983.
98. Kanamori H, Sasaki S, Ueda S, et al. [Graft-versus-leukemia
effect induced by abrupt discontinuation of cyclosporine Afollowing allogeneic bone marrow transplantation]. Rinsho
Ketsueki. 1997;38:643-646.
99. Locatelli F, Comoli P, Giorgiani G, et al. Infusion of donor-
derived peripheral blood leukocytes after transplantation of
cord blood progenitor cells can increase the graft-versus-
leukaemia effect. Leukemia. 1997;11:729-731.
100. Collins RH Jr., Goldstein S, Giralt S, et al. Donor leukocyte
infusions in acute lymphocytic leukemia. Bone Marrow Trans-
plant. 2000;26:511-516.
101. Bader P, Klingebiel T, Schaudt A, et al. Prevention of relapse in
pediatric patients with acute leukemias and MDS after alloge-
neic SCT by early immunotherapy initiated on the basis of
increasing mixed chimerism: a single center experience of 12
children. Leukemia. 1999;13:2079-2086.
102. Bader P, Holle W, Klingebiel T, et al. Mixed hematopoietic
chimerism after allogeneic bone marrow transplantation: the
impact of quantitative PCR analysis for prediction of relapse
and graft rejection in children. Bone Marrow Transplant. 1997;
19:697-702.
103. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed
chimerism is an important prognostic factor for unfavor-
able outcome in children with acute lymphoblastic leuke-
mia after allogeneic stem-cell transplantation: possible
role for pre-emptive immunotherapy? J Clin Oncol. 2004;
22:1696-1705.
104. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the
long and winding road: how should it be traveled? BoneMarrow
Transplant. 2008;42:569-579.
105. Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity
conditioning allogeneic stem cell transplantation for adult pa-
tients with acute lymphoblastic leukemia: a retrospective study
from the EuropeanGroup for Blood andMarrowTransplanta-
tion. Haematology. 2008;93:303-306.
106. Martino R, Giralt S, Caballero MD, et al. Allogeneic hemato-
poietic stem cell transplantation with reduced-intensity condi-
tioning in acute lymphoblastic leukemia: a feasibility study.
Haematology. 2003;88:555-560.
107. Hamaki T, Kami M, Kanda Y, et al. Reduced-intensity stem-
cell transplantation for adult acute lymphoblastic leukemia:
a retrospective study of 33 patients. Bone Marrow Transplant.
2005;35:549-556.
108. Bachanova V, Verneris MR, Defor T, Brunstein CG,
Weisdorf DJ. Prolonged survival in adults with acute lympho-
blastic leukemia after reduced-intensity conditioning with cord
blood or sibling donor transplantation. Blood. 2009;113:
2902-2905.
109. Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity
allogeneic transplantation in pediatric patients ineligible for
myeloablative therapy: results of the Pediatric Blood and
Marrow Transplant Consortium Study ONC0313. Blood.
2009;114:1429-1436.
110. Verneris MR, Eapen M, Duerst R, et al. Reduced intensity
conditioning regimens for allogeneic transplantation in chil-
dren with acute lymphoblastic leukemia. Biol Blood Marrow
Transplant. 2010 [Epub ahead of print].
111. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and
pharmacologic study of clofarabine in patients with refractory
or relapsed acute leukemia. Blood. 2003;102:2379-2386.
112. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucle-
oside analog, is active in pediatric patients with advanced leuke-
mia. Blood. 2004;103:784-789.
113. Sigalas P, Tourvas AD, Moulakakis A, Pangalis G,
Kontopidou F. Nelarabine induced complete remission in an
adult with refractory T-lineage acute lymphoblastic leukemia:
a case report and review of the literature. Leuk Res. 2009;33:
e61-e63.
114. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces
complete remissions in adults with relapsed or refractory
T-lineage acute lymphoblastic leukemia or lymphoblastic
lymphoma: Cancer and Leukemia Group B study 19801. Blood.
2007;109:5136-5142.
1498 Biol Blood Marrow Transplant 16:1467-1503, 2010D. L. Porter et al.115. ThomasDA, Kantarjian HM, StockW, et al. Phase 1 multicen-
ter study of vincristine sulfate liposomes injection and
dexamethasone in adults with relapsed or refractory acute lym-
phoblastic leukemia. Cancer. 2009;115:5490-5498.
116. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular
response to posttransplantation imatinib determines outcome
in MRD1 Philadelphia-positive acute lymphoblastic leukemia
(Ph1 ALL). Blood. 2005;106:458-463.
117. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S,
Fanin R. Nilotinib and donor lymphocyte infusion in the treat-
ment of Philadelphia-positive acute lymphoblastic leukemia
(Ph1 ALL) relapsing after allogeneic stem cell transplantation
and resistant to imatinib. Leuk Res. 2009;33:174-177.
118. Hayat A, McCann SR, Langabeer S, Irvine S, McMullin MF,
Conneally E. Effective use of imatinib-mesylate in the treat-
ment of relapsed chronic myeloid leukemia after allogeneic
transplantation. Haematology. 2009;94:296-298.
119. Burke MJ, Trotz B, Luo X, et al. Allo-hematopoietic cell
transplantation for Ph chromosome-positive ALL: impact of
imatinib on relapse and survival. Bone Marrow Transplant.
2009;43:107-113.
120. Rezvani K, Grube M, Brenchley JM, et al. Functional
leukemia-associated antigen-specific memory CD81 T cells
exist in healthy individuals and in patients with chronic mye-
logenous leukemia before and after stem cell transplantation.
Blood. 2003;102:2892-2900.
121. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of
GVHD, GVL, and graft rejection: considerations for the allo-
geneic transplantation therapy of leukemia and lymphoma.
Leuk Lymphoma. 2000;38:221-234.
122. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor
lymphocyte infusions expanded and activated ex vivo via CD3/
CD28 costimulation. Blood. 2006;107:1325-1331.
123. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA,
Gress RE. Thymic-independent T cell regeneration occurs
via antigen-driven expansion of peripheral T cells resulting in
a repertoire that is limited in diversity and prone to skewing.
J Immunol. 1996;156:4609-4616.
124. Rosenberg SA, Dudley ME. Cancer regression in patients with
metastatic melanoma after the transfer of autologous antitumor
lymphocytes. Proc Natl Acad Sci USA. 2004;101(Suppl 2):
14639-14645.
125. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be
rendered specific for CD19: toward the selective augmentation
of the graft-versus-B-lineage leukemia effect. Blood. 2003;101:
1637-1644.
126. Rossig C, Pscherer S, Landmeier S, Altvater B, Jurgens H,
Vormoor J. Adoptive cellular immunotherapy with CD19-
specific T cells. Klin Padiatr. 2005;217:351-356.
127. Kohler G, Milstein C. Continuous cultures of fused cells se-
creting antibody of predefined specificity. Nature. 1975;256:
495-497.
128. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Re-
mission of adult acute lymphocytic leukaemia with alemtuzu-
mab. Leukemia. 2004;18:1557-1558.
129. Corbacioglu S, Eber S, Gungor T, Hummerjohann J, Niggli F.
Induction of long-term remission of a relapsed childhood B-
acute lymphoblastic leukemia with rituximab chimeric
anti-CD20monoclonal antibody and autologous stemcell trans-
plantation. J Pediatr Hematol Oncol. 2003;25:327-329.
130. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O,
Chapa-Rodriguez A, Gomez-Almaguer D. Effectiveness of in-
trathecal rituximab in patients with acute lymphoblastic leu-
kaemia relapsed to the CNS and resistant to conventional
therapy. Br J Haematol. 2009;144:794-795.
131. Griffin TC, Weitzman S, Weinstein H, et al. A study of ritux-
imab and ifosfamide, carboplatin, and etoposide chemotherapy
in children with recurrent/refractory B-cell (CD201) non-
Hodgkin lymphoma and mature B-cell acute lymphoblastic
leukemia: a report from the Children’s Oncology Group.
Pediatr Blood Cancer. 2009;52:177-181.132. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunother-
apy reinduction with epratuzumab in children with acute lym-
phoblastic leukemia in marrow relapse: a Children’s Oncology
Group Pilot Study. J Clin Oncol. 2008;26:3756-3762.
133. ThomasDA, Faderl S, O’Brien S, et al. Chemoimmunotherapy
with hyper-CVAD plus rituximab for the treatment of adult
Burkitt and Burkitt-type lymphoma or acute lymphoblastic
leukemia. Cancer. 2006;106:1569-1580.
134. Piccaluga PP, Martinelli G, Malagola M, et al. Anti-leukemic
and anti-GVHD effects of campath-1H in acute lymphoblastic
leukemia relapsed after stem-cell transplantation. Leuk Lym-
phoma. 2004;45:731-733.
135. Lang P, Barbin K, Feuchtinger T, et al. Chimeric CD19
antibody mediates cytotoxic activity against leukemic
blasts with effector cells from pediatric patients who received
T-cell-depleted allografts. Blood. 2004;103:3982-3985.
136. Zwaan CM, Reinhardt D, Jurgens H, et al. Gemtuzumab ozo-
gamicin in pediatric CD33-positive acute lymphoblastic leuke-
mia: first clinical experiences and relation with cellular
sensitivity to single agent calicheamicin. Leukemia. 2003;17:
468-470.
137. Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22
immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive
hematologic malignancies of childhood: preclinical studies
and phase I clinical trial. Clin Cancer Res. 2010;16:
1894-1903.
138. Matthews DC, Appelbaum FR, Eary JF, et al. Development of
a marrow transplant regimen for acute leukemia using targeted
hematopoietic irradiation delivered by 131I-labeled anti-
CD45 antibody, combined with cyclophosphamide and total
body irradiation. Blood. 1995;85:1122-1131.
139. Kaminetzky D, Hymes KB. Denileukin diftitox for the treat-
ment of cutaneous T-cell lymphoma. Biologics. 2008;2:717-724.
140. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in can-
cer patients by very low doses of a T cell-engaging antibody.
Science. 2008;321:974-977.
141. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW,
Keilholz U. Complete remission in a patient with recurrent
acute myeloid leukemia induced by vaccination with WT1
peptide in the absence of hematological or renal toxicity.
Leukemia. 2004;18:165-166.
142. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of
hematologic malignancy. Hematology Am Soc Hematol Educ
Program. 2003;331-349.
143. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering
artificial antigen-presenting cells to express a diverse array of
co-stimulatory molecules. Mol Ther. 2007;15:981-988.
144. HainingWN, Cardoso AA, Keczkemethy HL, et al. Failure to
define window of time for autologous tumor vaccination in
patients with newly diagnosed or relapsed acute lymphoblastic
leukemia. Exp Hematol. 2005;33:286-294.
145. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation
with reduced-intensity conditioning for Hodgkin and non-
Hodgkin lymphoma: importance of histology for outcome.
Biol Blood Marrow Transplant. 2008;14:418-425.
146. Glass B, Nickelsen M, Dreger P, et al. Reduced-intensity con-
ditioning prior to allogeneic transplantation of hematopoietic
stem cells: the need for T cells early after transplantation to
induce a graft-versus-lymphoma effect. Bone Marrow Trans-
plant. 2004;34:391-397.
147. Petersen FB, Appelbaum FR, Buckner CD, et al. Simulta-
neous infusion of high-dose cytosine arabinoside with cy-
clophosphamide followed by total body irradiation and
marrow infusion for the treatment of patients with ad-
vanced hematological malignancy. Bone Marrow Transplant.
1988;6:619-624.
148. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical
review, policy proposals, and immunobiology. Biol Blood
Marrow Transplant. 2004;9:579-590.
149. Van Besien KW, de Lima M, Giralt SA, et al. Management of
lymphoma recurrence after allogeneic transplantation: the
Biol Blood Marrow Transplant 16:1467-1503, 2010 1499NCI First International Workshop on alloHSCTrelevance of graft-versus-lymphoma effects. Bone Marrow
Transplant. 1997;19:977-982.
150. Milojkovic D, Mijovic A, Taylor CG, Mufti GJ, Pagliuca A.
Rituximab salvage following relapse after allogeneic bone
marrow transplantation for non-Hodgkin’s lymphoma. Br J
Haematol. 2000;110:1013-1014.
151. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W.
Cross-priming of cytotoxic T cells promoted by apoptosis-
inducing tumor cell reactive antibodies? J Clin Immunol.
2002;22:124-130.
152. Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applica-
tions of rituximab in allogeneic stem cell transplantation:
Anti-tumor and immunomodulatory effects. Cancer Treat Rev.
2009;35:653-661.
153. Au WY, Lie AK, Siu LL, et al. Treatment of lymphoma re-
lapses after allogeneic hematopoietic stem cell transplantation
with intensive chemotherapy followed by infusion of hemato-
poietic stem cell from the original donor. Ann Hematol. 2003;
82:548-551.
154. Gupta NK, Barker JN, Young JW, Noy A. Fourth complete
remission with immunosuppression withdrawal and irinote-
can after both autologous and allogeneic transplants for dif-
fuse large B cell lymphoma. Leuk Lymphoma. 2009;50:
2075-2077.
155. Behre G, Christopeit M, Weber T. Involved field radiation
therapy and donor lymphocyte infusion for relapsed or re-
fractory non-Hodgkin lymphoma after allogeneic hemato-
poietic stem cell transplantation. Int J Hematol. 2008;88:
463-464.
156. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade
with ipilimumab to treat relapse of malignancy after allogeneic
hematopoietic cell transplantation.Blood. 2009;113:1581-1588.
157. Tueger S, Chen FE, Ahsan G, et al. Thalidomide induced
remission of refractory diffuse large B-Cell Lymphoma post-
allogeneic SCT. Haematology. 2006;91:ECR16.
158. Kiss TL, Spaner D, Daly AS, et al. Complete remission of
tumour with interleukin 2 therapy in a patient with non-
Hodgkin’s lymphoma post allogeneic bone marrow transplant
associated with polyclonal T-cell bone marrow lymphocytosis.
Br J Haematol. 2003;120:523-525.
159. Kawano I, Tsukada J, Toda Y, et al. [Remission induction of
refractory diffuse large B-cell lymphoma with allogeneic
peripheral blood stem cell transplantation followed by
interferon-alpha and donor lymphocyte infusion]. Rinsho
Ketsueki. 2004;45:155-160.
160. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T,
Appelbaum FR. Second allogeneic transplantation after failure
of first autologous transplantation. Biol Blood Marrow Trans-
plant. 2000;3:272-279.
161. Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allo-
geneic hematopoietic stem cell transplantation in patients who
relapse after autologous stem cell transplantation for lym-
phoma: a report of the international bone marrow transplant
registry. Blood. 2004;104:3797-2803.
162. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experi-
ence with allogeneic stem cell transplantation for relapsed
follicular lymphoma after nonmyeloablative conditioning
with fludarabine, cyclophosphamide, and rituximab. Blood.
2008;111:5530-5536.
163. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative
allogeneic hematopoietic cell transplantation in relapsed,
refractory, and transformed indolent non-Hodgkin’s lym-
phoma. J Clin Oncol. 2008;26:211-217.
164. Perez-Simon JA,KottaridisPD,MartinoR, et al.Nonmyeloabla-
tive transplantation with or without alemtuzumab: comparison
between 2 prospective studies in patients with lymphoprolifera-
tive disorders. Blood. 2002;100:3121-3127.
165. Morris E, Thomson K, Craddock C, et al. Outcome following
alemtuzumab (CAMPATH-1H)-containing reduced intensity
allogeneic transplant regimen for relapsed and refractory non-
Hodgkin’s lymphoma (NHL). Blood. 2004;104:3865-3871.166. Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of
BEAM-autologous and BEAM-alemtuzumab allogeneic
transplantation in relapsed advanced stage follicular lym-
phoma. Br J Haematol. 2008;141:235-243.
167. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term
survival after reduced-intensity allogeneic transplantation for
multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin
Oncol. 2009;27:426-432.
168. Sirvent A,DhedinN,MichalletM, et al. Low non-relapsemor-
tality and prolonged long-term survival after reduced-intensity
allogeneic stem cell transplantation for relapsed or refractory
diffuse large B-cell lymphoma: Report of the Societe Francaise
de Greffe de Moelle et de Therapie Cellulaire. Biol Blood
Marrow Transplant. 2010;16:78-85.
169. Bishop MR, Dean RM, Steinberg SM, et al. Clinical evidence
of a graft-versus-lymphoma effect against relapsed diffuse large
B-cell lymphoma after allogeneic hematopoietic stem-cell
transplantation. Ann Oncol. 2008;19:1935-1940.
170. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hema-
topoietic cell transplantation after fludarabine and 2 Gy total
body irradiation for relapsed and refractory mantle cell
lymphoma. Blood. 2004;104:3535-3542.
171. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic
stem-cell transplantation for advanced/recurrent mantle-cell
lymphoma. J Clin Oncol. 2003;21:4407-4412.
172. Tam CS, Bassett R, Ledesma C, et al. Mature results of the
M.D. Anderson Cancer Center risk-adapted transplantation
strategy in mantle cell lymphoma. Blood. 2009;113:
4144-4152.
173. Tam CS, Khouri IF. Autologous and allogeneic stem cell
transplantation: rising therapeutic promise for mantle cell lym-
phoma. Leuk Lymphoma. 2009;50:1239-1248.
174. Shiratori S, Yasumoto A, Tanaka J, et al. A retrospective
analysis of allogeneic hematopoietic stem cell transplantation
for adult T cell leukemia/lymphoma (ATL): clinical impact
of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow
Transplant. 2008;14:817-823.
175. de Lavallade H, Cassier PA, Bouabdallah R, et al. Sustained
response after reduced-intensity conditioning allogeneic stem
cell transplantation for patients with relapsed peripheral
T-cell non-Hodgkin lymphoma. Br J Haematol. 2008;142:
848-850.
176. Hamadani M, Awan FT, Elder P, et al. Allogeneic hematopoi-
etic stem cell transplantation for peripheral T cell lymphomas;
evidence of graft-versus-T cell lymphoma effect. Biol Blood
Marrow Transplant. 2008;14:480-483.
177. Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell
transplantation is able to induce long-term remissions in an-
gioimmunoblastic T-cell lymphoma: a retrospective study
from the lymphoma working party of the European group for
blood and marrow transplantation. J Clin Oncol. 2009;27:
3951-3958.
178. Sorror ML, Storer BE, Maloney DG, Sandmaier BM,
Martin PJ, Storb R. Outcomes after allogeneic hematopoietic
cell transplantation with nonmyeloablative or myeloablative
conditioning regimens for treatment of lymphoma and chronic
lymphocytic leukemia. Blood. 2008;111:446-452.
179. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in
patients with malignant diseases given allogeneic hematopoi-
etic cell transplantation after nonmyeloablative conditioning.
Blood. 2007;110:2744-2748.
180. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow
transplants from HLA-identical siblings in advanced Hodg-
kin’s disease. J Clin Oncol. 1996;14:572-578.
181. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic,
syngeneic, and autologous marrow transplantation for Hodg-
kin’s disease: the 21-year Seattle experience. J Clin Oncol.
1993;11:2342-2350.
182. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of
a graft-versus-lymphoma effect associated with allogeneic bone
marrow transplantation. Blood. 1991;77:649-653.
1500 Biol Blood Marrow Transplant 16:1467-1503, 2010D. L. Porter et al.183. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results
of blood andmarrow transplantation forHodgkin’s lymphoma.
J Clin Oncol. 2001;19:4314-4321.
184. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of
a graft-versus-Hodgkin’s-lymphoma effect after reduced-
intensity allogeneic transplantation. Lancet. 2005;365:
1934-1941.
185. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity
allogeneic stem cell transplantation in relapsed and refractory
Hodgkin’s disease: low transplant-relatedmortality and impact
of intensity of conditioning regimen. Bone Marrow Transplant.
2005;35:943-951.
186. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative
stem cell transplantation is an effective therapy for refractory
or relapsed hodgkin lymphoma: results of a Spanish prospec-
tive cooperative protocol. Biol Blood Marrow Transplant. 2006;
12:172-183.
187. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell
transplantation following reduced-intensity conditioning can
induce durable clinical and molecular remissions in relapsed
lymphomas: pre-transplant disease status and histotype heavily
influence outcome. Leukemia. 2007;21:2316-2323.
188. Majhail NS, Weisdorf DJ, Wagner JE, DeFor TE,
Brunstein CG, Burns LJ. Comparable results of umbilical
cord blood and HLA-matched sibling donor hematopoietic
stem cell transplantation after reduced-intensity preparative
regimen for advanced Hodgkin lymphoma. Blood. 2006;107:
3804-3807.
189. Porter DL, Stadtmauer EA, Lazarus HM. ‘‘GVHD’’: graft-
versus-host disease or graft-versus-Hodgkin’s disease? An old
acronym with new meaning. Bone Marrow Transplant. 2003;
31:739-746.
190. Robinson SP, Sureda A, Canals C, et al. Reduced intensity
conditioning allogeneic stem cell transplantation for Hodg-
kin’s lymphoma: identification of prognostic factors predicting
outcome. Haematology. 2009;94:230-238.
191. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor
lymphocyte infusions following reduced intensity transplanta-
tion: toxicity, chimerism, and disease responses. Blood. 2004;
103:1548-1556.
192. Anderlini P, SalibaR,AcholonuS, et al. Fludarabine-melphalan
as a preparative regimen for reduced-intensity conditioning
allogeneic stem cell transplantation in relapsed and refractory
Hodgkin’s lymphoma: the updated M.D. Anderson Cancer
Center experience. Haematology. 2008;93:257-264.
193. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity condi-
tioning for allogeneic haematopoietic stem cell transplantation
in relapsed and refractory Hodgkin lymphoma: impact of
alemtuzumab and donor lymphocyte infusions on long-term
outcomes. Br J Haematol. 2007;139:70-80.
194. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J.
Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am
J Pathol. 1987;129:86-91.
195. Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Rowe M,
Young LS. Activation of Epstein-Barr virus replication in
Hodgkin and Reed-Sternberg cells. Blood. 1991;78:1162-1165.
196. Niedobitek G, Kremmer E, Herbst H, et al. Immunohisto-
chemical detection of the Epstein-Barr virus-encoded latent
membrane protein 2A in Hodgkin’s disease and infectious
mononucleosis. Blood. 1997;90:1664-1672.
197. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus
latent membrane protein expression in Hodgkin and Reed-
Sternberg cells. Proc Natl Acad Sci USA. 1991;88:4766-4770.
198. NiedobitekG,YoungLS.Epstein-Barr virus andnon-Hodgkin’s
lymphomas. In: Magrath IV, editor. The Non-Hodgkin’s
Lymphomas, 2nd ed. London: Arnold; 1997 p. 309-329.
199. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T
lymphocyte therapy for Epstein-Barr virus1 Hodgkin’s
disease. J Exp Med. 2004;200:1623-1633.
200. BollardCM,Gottschalk S, LeenAM, et al. Complete responses
of relapsed lymphoma following genetic modification oftumor-antigen presenting cells and T-lymphocyte transfer.
Blood. 2007;110:2838-2845.
201. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus
specific cytotoxic T lymphocytes expressing the anti-
CD30zeta artificial chimeric T-cell receptor for immunother-
apy of Hodgkin disease. Blood. 2007;110:2620-2630.
202. Kroger N, Bacher U, Bader P, et al. NCI First International
Workshop on the Biology, Prevention and Treatment of
Relapse after Allogeneic Hematopoietic Stem Cell Transplan-
tation: Report from the Committee on Disease-Specific
Methods and Strategies for Monitoring Relapse Following
Allogeneic StemCell Transplantation. Part II: Chronic Leuke-
mias, Myeloproliferative Neoplasms and LymphoidMalignan-
cies. Biol Blood Marrow Transplant. 2010 [Epub ahead of print].
203. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-
up of patients with advanced chronic lymphocytic leukemia
treated with allogeneic hematopoietic cell transplantation
after nonmyeloablative conditioning. J Clin Oncol. 2008;26:
4912-4920.
204. Delgado J, Thomson K, Russell N, et al. Results of
alemtuzumab-based reduced-intensity allogeneic transplanta-
tion for chronic lymphocytic leukemia: a British Society of
Blood and Marrow Transplantation Study. Blood. 2006;107:
1724-1730.
205. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic
stem cell transplantation for chronic lymphocytic leukemia:
impact of rituximab on immunomodulation and survival.
Exp Hematol. 2004;32:28-35.
206. Schetelig J, Thiede C, BornhauserM, et al. Evidence of a graft-
versus-leukemia effect in chronic lymphocytic leukemia after
reduced-intensity conditioning and allogeneic stem-cell trans-
plantation: the Cooperative German Transplant Study Group.
J Clin Oncol. 2003;21:2747-2753.
207. Brown JR, Kim HT, Li S, et al. Predictors of improved
progression-free survival after nonmyeloablative allogeneic
stem cell transplantation for advanced chronic lymphocytic
leukemia. Biol Blood Marrow Transplant. 2006;12:1056-1064.
208. Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplan-
tation in lymphoma: current status. Haematology. 2007;92:
1533-1548.
209. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell
transplantation provides durable disease control in poor-risk
chronic lymphocytic leukemia:long-term clinical and MRD
results of the GCLLSGCLL3X trial. Blood. 2010 [Epub ahead
of print].
210. Delgado J, Pillai S, Benjamin R, et al. The effect of in vivo T
cell depletion with alemtuzumab on reduced-intensity alloge-
neic hematopoietic cell transplantation for chronic lympho-
cytic leukemia. Biol Blood Marrow Transplant. 2008;14:
1288-1297.
211. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic
cell transplantation after nonmyeloablative conditioning for
advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;
23:3819-3829.
212. Hoogendoorn M, Jedema I, Barge RM, et al. Characterization
of graft-versus-leukemia responses in patients treated for
advanced chronic lymphocytic leukemia with donor lympho-
cyte infusions after in vitro T-cell depleted allogeneic stem
cell transplantation following reduced-intensity conditioning.
Leukemia. 2007;21:2569-2574.
213. RitgenM, Bottcher S, Stilgenbauer S, et al. Quantitative MRD
monitoring identifies distinct GVL response patterns after
allogeneic stem cell transplantation for chronic lymphocytic
leukemia: results from the GCLLSG CLL3X trial. Leukemia.
2008;22:1377-1386.
214. Moreno C, Villamor N, Colomer D, et al. Clinical significance
of minimal residual disease, as assessed by different techniques,
after stem cell transplantation for chronic lymphocytic leuke-
mia. Blood. 2006;107:4563-4569.
215. Byrne JL, Fairbairn J, Davy B, Carter IG, Bessell EM,
Russell NH. Allogeneic transplantation for multiple myeloma:
Biol Blood Marrow Transplant 16:1467-1503, 2010 1501NCI First International Workshop on alloHSCTlate relapse may occur as localised lytic lesion/plasmacytoma
despite ongoing molecular remission. Bone Marrow Transplant.
2003;31:157-161.
216. Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B,
Kroger N. Minimal residual disease diagnostics in myeloid
malignancies in the post transplant period. BoneMarrow Trans-
plant. 2008;42:145-157.
217. Pavletic SZ, Zhou G, Sobocinski K, et al. Genetically identical
twin transplantation for chronic lymphocytic leukemia. Leuke-
mia. 2007;21:2452-2455.
218. Hardy NM, Grady C, Pentz R, et al. Bioethical considerations
of monoclonal B-cell lymphocytosis: donor transfer after
haematopoietic stem cell transplantation. Br J Haematol.
2007;139:824-831.
219. Caporaso N, Marti GE, Goldin L. Perspectives on familial
chronic lymphocytic leukemia: genes and the environment.
Semin Hematol. 2004;41:201-206.
220. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B
lymphocytes with the characteristics of ‘‘indolent’’ chronic
lymphocytic leukemia are present in 3.5% of adults with
normal blood counts. Blood. 2002;100:635-639.
221. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for
monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:
325-332.
222. Marti GE, Carter P, Abbasi F, et al. B-cell monoclonal lym-
phocytosis and B-cell abnormalities in the setting of familial
B-cell chronic lymphocytic leukemia. Cytometry. 2003;52:1-12.
223. Rawstron AC, YuilleMR, Fuller J, et al. Inherited predisposition
to CLL is detectable as subclinical monoclonal B-lymphocyte
expansion. Blood. 2002;100:2289-2290.
224. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and al-
logeneic stem cell transplantations for poor-risk chronic lym-
phocytic leukemia. Blood. 2005;106:4389-4396.
225. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor
effects after allogeneic hematopoietic cell transplantation
with nonmyeloablative conditioning. J Clin Oncol. 2005;23:
1993-2003.
226. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality
and graft-versus-leukemia activity after allogeneic stem
cell transplantation for chronic lymphocytic leukemia using
intensity-reduced conditioning. Leukemia. 2003;17:841-848.
227. RondonG, Giralt S, Huh Y, et al. Graft-versus-leukemia effect
after allogeneic bone marrow transplantation for chronic lym-
phocytic leukemia. Bone Marrow Transplant. 1996;18:669-672.
228. Porter DL, Collins RH Jr., Shpilberg O, et al. Long-term
follow-up of patients who achieved complete remission after
donor leukocyte infusions. Biol Blood Marrow Transplant.
1999;5:253-261.
229. Huff CA, Fuchs EJ, Smith BD, et al. Graft-versus-host reac-
tions and the effectiveness of donor lymphocyte infusions.
Biol Blood Marrow Transplant. 2006;12:414-421.
230. BethgeWA,Hegenbart U, StuartMJ, et al. Adoptive immuno-
therapy with donor lymphocyte infusions after allogeneic he-
matopoietic cell transplantation following nonmyeloablative
conditioning. Blood. 2004;103:790-795.
231. RussellNH,Byrne JL,FaulknerRD,GilyeadM,Das-GuptaEP,
Haynes AP. Donor lymphocyte infusions can result in sustained
remissions in patients with residual or relapsed lymphoid malig-
nancy following allogeneic haemopoietic stem cell transplanta-
tion. Bone Marrow Transplant. 2005;36:437-441.
232. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate
to donor lymphocyte infusion after allogeneic stem cell trans-
plantation for indolent non-Hodgkin lymphoma. Biol Blood
Marrow Transplant. 2008;14:50-58.
233. Ravandi F, O’Brien S. Immune defects in patients with chronic
lymphocytic leukemia. Cancer Immunol Immunother. 2006;55:
197-209.
234. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28
costimulation on long-term proliferation of CD41 T cells in
the absence of exogenous feeder cells. J Immunol. 1997;159:
5921-5930.235. Buhmann R, Simoes B, Stanglmaier M, et al. Immunotherapy
of recurrent B-cell malignancies after allo-SCT with Bi20
(FBTA05), a trifunctional anti-CD3  anti-CD20 antibody
and donor lymphocyte infusion. Bone Marrow Transplant.
2009;43:383-397.
236. Kochenderfer JN,YuZ,FrasheriD,RestifoNP,Rosenberg SA.
Adoptive transfer of syngeneicT cells transducedwith a chime-
ric antigen receptor that recognizesmurineCD19 can eradicate
lymphoma and normal B cells. Blood. 2010.
237. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treat-
ment of chronic lymphocytic leukemia with genetically tar-
geted autologous T cells: case report of an unforeseen
adverse event in a phase I clinical trial. Mol Ther. 2010;18:
666-668.
238. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM,
Rosenberg SA. Case report of a serious adverse event follow-
ing the administration of T cells transduced with a chimeric
antigen receptor recognizing ERBB2. Mol Ther. 2010;18:
843-851.
239. Davies JK, Singh H, Huls H, et al. Combining CD19 redirec-
tion and alloanergization to generate tumor-specific human
T cells for allogeneic cell therapy of B-cell malignancies.Cancer
Res. 2010;70:3915-3924.
240. PalmaM, Adamson L,Hansson L, et al. Development of a den-
dritic cell-based vaccine for chronic lymphocytic leukemia.
Cancer Immunol Immunother. 2008;57:1705-1710.
241. Hus I, SchmittM, Tabarkiewicz J, et al. Vaccination of B-CLL
patients with autologous dendritic cells can change the
frequency of leukemia antigen-specific CD81 T cells as well
as CD41CD251FoxP31 regulatory T cells toward an
antileukemia response. Leukemia. 2008;22:1007-1017.
242. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients
with acute myeloid leukemia—definition of leukemia-
associated antigens and current clinical protocols targeting
these antigens. Haematology. 2006;91:1653-1661.
243. Friedrichs B, Siegel S, Andersen MH, Schmitz N, Zeis M.
Survivin-derived peptide epitopes and their role for induction
of antitumor immunity in hematological malignancies. Leuk
Lymphoma. 2006;47:978-985.
244. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared
tumor-associated antigen expressed in a broad variety of malig-
nancies and recognized by specific cytotoxic T cells. Blood.
2003;102:571-576.
245. Zhu K, Qin H, Cha SC, et al. Survivin DNA vaccine generated
specific antitumor effects in pancreatic carcinoma and lym-
phoma mouse models. Vaccine. 2007;25:7955-7961.
246. Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of first
salvage therapy for patients refractory to a fludarabine regimen
in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:
1755-1762.
247. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, et al.
Characterisation of TP53 abnormalities in chronic lympho-
cytic leukaemia. Hematol J. 2004;5:47-54.
248. Wattel E, PreudhommeC, Hecquet B, et al. p53 mutations are
associated with resistance to chemotherapy and short survival
in hematologic malignancies. Blood. 1994;84:3148-3157.
249. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion pre-
dicts for poor survival and non-response to therapy with purine
analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
250. Byrd JC, Smith L, HackbarthML, et al. Interphase cytogenetic
abnormalities in chronic lymphocytic leukemia may predict
response to rituximab. Cancer Res. 2003;63:36-38.
251. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hemato-
poietic stem-cell transplantation for chronic lymphocytic
leukemia with 17p deletion: a retrospective European Group
for Blood and Marrow Transplantation analysis. J Clin Oncol.
2008;26:5094-5100.
252. Moreno C, VillamorN, Colomer D, et al. Allogeneic stem-cell
transplantation may overcome the adverse prognosis of unmu-
tated VH gene in patients with chronic lymphocytic leukemia.
J Clin Oncol. 2005;23:3433-3438.
1502 Biol Blood Marrow Transplant 16:1467-1503, 2010D. L. Porter et al.253. Tam CS, O’Brien S, Lerner S, et al. The natural history of
fludarabine-refractory chronic lymphocytic leukemia patients
who fail alemtuzumab or have bulky lymphadenopathy. Leuk
Lymphoma. 2007;48:1931-1939.
254. Tsimberidou AM, KeatingMJ, Giles FJ, et al. Fludarabine and
mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer. 2004;100:2583-2591.
255. O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the flu-
darabine and cyclophosphamide combination regimen in
chronic lymphocytic leukemia. JClinOncol. 2001;19:1414-1420.
256. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy
with fludarabine, cyclophosphamide, and rituximab for
relapsed and refractory chronic lymphocytic leukemia. J Clin
Oncol. 2005;23:4070-4078.
257. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclo-
phosphamide: an effective new regimen in previously treated
patients with chronic lymphocytic leukemia. J Clin Oncol.
2003;21:1278-1284.
258. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclo-
phosphamide, and rituximab is an active, well-tolerated regi-
men for patients with previously treated chronic lymphocytic
leukemia. J Clin Oncol. 2006;24:1575-1581.
259. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old
drug. J Clin Oncol. 2009;27:1492-1501.
260. Roue G, Lopez-Guerra M, Milpied P, et al. Bendamustine is
effective in p53-deficient B-cell neoplasms and requires oxida-
tive stress and caspase-independent signaling. Clin Cancer Res.
2008;14:6907-6915.
261. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell
depleting therapy in graft versus host disease after allogeneic
hematopoietic cell transplant. Leuk Lymphoma. 2010;51:
376-389.
262. Anderson KC. Lenalidomide and thalidomide: mechanisms of
action—similarities and differences. Semin Hematol. 2005;42:
S3-S8.
263. Chanan-Khan A,Miller KC,Musial L, et al. Clinical efficacy of
lenalidomide in patients with relapsed or refractory chronic
lymphocytic leukemia: results of a phase II study. J Clin Oncol.
2006;24:5343-5349.
264. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces
complete and partial remissions in patients with relapsed and
refractory chronic lymphocytic leukemia. Blood. 2008;111:
5291-5297.
265. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of
lenalidomide are associated with unacceptable toxicity includ-
ing life-threatening tumor flare in patients with chronic lym-
phocytic leukemia. J Clin Oncol. 2008;26:2519-2525.
266. Teeling JL, French RR, Cragg MS, et al. Characterization of
new humanCD20monoclonal antibodies with potent cytolytic
activity against non-Hodgkin lymphomas. Blood. 2004;104:
1793-1800.
267. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy
of ofatumumab, a fully human monoclonal anti-CD20 anti-
body, in patients with relapsed or refractory B-cell chronic
lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:
1094-1100.
268. Mussai F, Campana D, Bhojwani D, et al. Cytotoxicity of the
anti-CD22 immunotoxin HA22 (CAT-8015) against paediat-
ric acute lymphoblastic leukaemia. Br J Haematol. 2010.
269. O’Brien S, Moore JO, Boyd TE, et al. Randomized phase III
trial of fludarabine plus cyclophosphamide with or without
oblimersen sodium (Bcl-2 antisense) in patients with relapsed
or refractory chronic lymphocytic leukemia. J Clin Oncol.
2007;25:1114-1120.
270. de Vries EG, de JS. Exploiting the apoptotic route for cancer
treatment: a single hit will rarely result in a home run. J Clin
Oncol. 2008;26:5151-5153.
271. Altieri DC. Survivin, cancer networks and pathway-directed
drug discovery. Nat Rev Cancer. 2008;8:61-70.
272. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J.
Mediation of apoptosis by and antitumor activity of lumilixi-mab in chronic lymphocytic leukemia cells and CD231 lym-
phoma cell lines. Blood. 2008;111:1594-1602.
273. Byrd JC, Castro J, O’Brien S, et al. Comparison of results from
a phase 1/2 study of lumiliximab (anti-CD23) in combination
with FCR for patients with relapsed CLL with published
FCR results. Blood. 2006;108:14a.
274. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro
and in vivo significance in chronic lymphocytic leukemia and is
associated with other poor prognostic markers. Blood. 2008;
112:3807-3817.
275. Schliep S, Decker T, Schneller F, Wagner H, Hacker G.
Functional evaluation of the role of inhibitor of apoptosis
proteins in chronic lymphocytic leukemia. Exp Hematol.
2004;32:556-562.
276. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered
using a pharmacologically derived schedule is associated with
marked clinical efficacy in refractory, genetically high-risk
chronic lymphocytic leukemia. Blood. 2007;109:399-404.
277. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of
flavopiridol in relapsed chronic lymphocytic leukemia demon-
strating high response rates in genetically high-risk disease.
J Clin Oncol. 2009;27:6012-6018.
278. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in
chronic graft-versus-host disease. Haematology. 2008;93:
1702-1711.
279. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion
in autoimmune diseases: potential effects on T cells. Clin
Immunol. 2008;127:280-285.
280. Corradini P, Voena C, Tarella C, et al. Molecular and clinical
remissions in multiple myeloma: role of autologous and alloge-
neic transplantation of hematopoietic cells. J Clin Oncol. 1999;
17:208-215.
281. Martinelli G, Terragna C, Zamagni E, et al. Molecular remis-
sion after allogeneic or autologous transplantation of hemato-
poietic stem cells for multiple myeloma. J Clin Oncol. 2000;18:
2273-2281.
282. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic
marrow transplantation for multiple myeloma: an analysis of
risk factors on outcome. Blood. 1996;88:2787-2793.
283. Hunter HM, Peggs K, Powles R, et al. Analysis of outcome
following allogeneic haemopoietic stem cell transplantation
for myeloma using myeloablative conditioning—evidence for
a superior outcome using melphalan combined with total
body irradiation. Br J Haematol. 2005;128:496-502.
284. Kroger N, Einsele H, Wolff D, et al. Myeloablative intensi-
fied conditioning regimen with in vivo T-cell depletion
(ATG) followed by allografting in patients with advanced
multiple myeloma. A phase I/II study of the German Study-
group Multiple Myeloma (DSMM). Bone Marrow Transplant.
2003;31:973-979.
285. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF,
Niederwieser D, Gahrton G. Reduced-intensity conditioning
for myeloma: lower nonrelapse mortality but higher relapse
rates compared with myeloablative conditioning. Blood. 2007;
109:3588-3594.
286. Perez-Simon JA, Sureda A, Fernandez-Aviles F, et al. Reduced-
intensity conditioning allogeneic transplantation is associated
with a high incidence of extramedullary relapses in multiple
myeloma patients. Leukemia. 2006;20:542-545.
287. MinnemaMC, van deDonkNW,Zweegman S, et al. Extrame-
dullary relapses after allogeneic non-myeloablative stem cell
transplantation in multiple myeloma patients do not negatively
affect treatment outcome. Bone Marrow Transplant. 2008;41:
779-784.
288. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N,
Barlogie B. Graft-versus-myeloma effect: proof of principle.
Blood. 1996;87:1196-1198.
289. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of
graft-versus-host disease is the major predictive factor for re-
sponse to donor lymphocyte infusions in multiple myeloma.
Blood. 2004;103:4362-4364.
Biol Blood Marrow Transplant 16:1467-1503, 2010 1503NCI First International Workshop on alloHSCT290. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infu-
sions for multiple myeloma. Bone Marrow Transplant. 2000;26:
1179-1184.
291. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK,
Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet.
1996;96:800-801.
292. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J.
Adoptive immunotherapy for relapsed multiple myeloma after
allogeneic bone marrow transplantation (BMT): evidence for
a graft-versus-myeloma effect. Leukemia. 1997;11:281-283.
293. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL,
Verdonck LF. Donor leukocyte infusions are effective in
relapsed multiple myeloma after allogeneic bone marrow
transplantation. Blood. 1997;90:4206-4211.
294. Ayuk F, Shimoni A,Nagler A, et al. Efficacy and toxicity of low-
dose escalating donor lymphocyte infusion given after reduced
intensity conditioning allograft for multiple myeloma. Leuke-
mia. 2004;18:659-662.
295. Alyea E,Weller E, Schlossman R, et al. T-cell-depleted alloge-
neic bone marrow transplantation followed by donor lympho-
cyte infusion in patients with multiple myeloma: induction of
graft-versus-myeloma effect. Blood. 2001;98:934-939.
296. Peggs KS,Mackinnon S,Williams CD, et al. Reduced-intensity
transplantation with in vivo T-cell depletion and adjuvant dose-
escalating donor lymphocyte infusions for chemotherapy-
sensitive myeloma: limited efficacy of graft-versus-tumor
activity. Biol Blood Marrow Transplant. 2003;9:257-265.
297. Kroger N, Kruger W, Renges H, et al. Donor lymphocyte
infusion enhances remission status in patients with persistent
disease after allografting for multiple myeloma. Br J Haematol.
2001;112:421-423.
298. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic
factors for donor lymphocyte infusions following non-
myeloablative allogeneic stem cell transplantation in multiple
myeloma. Bone Marrow Transplant. 2006;37:1135-1141.
299. Mielke S, Nunes R, Rezvani K, et al. A clinical-scale selective
allodepletion approach for the treatment of HLA-mismatched
and matched donor-recipient pairs using expanded T lympho-
cytes as antigen-presenting cells and a TH9402-based photode-
pletion technique. Blood. 2008;111:4392-4402.
300. Davies FE, Raje N, Hideshima T, et al. Thalidomide and
immunomodulatory derivatives augment natural killer cell
cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
301. Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalido-
mide and donor lymphocyte infusion as adoptive immunother-
apy after allogeneic stem cell transplantation in patients with
multiple myeloma. Blood. 2004;104:3361-3363.
302. MohtyM, AttalM,Marit G, et al. Thalidomide salvage therapy
following allogeneic stem cell transplantation for multiple
myeloma: a retrospective study from the Intergroupe Franco-
phone du Myelome (IFM) and the Societe Francaise de Greffe
de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow
Transplant. 2005;35:165-169.
303. Lioznov M, El-Cheikh J Jr., Hoffmann F, et al. Lenalidomide
as salvage therapy after allo-SCT for multiple myeloma is
effective and leads to an increase of activated NK (NKp44
(1)) and T (HLA-DR(1)) cells. Bone Marrow Transplant.
2010;45:349-353.
304. Minnema MC, van der Veer MS, Aarts T, Emmelot M,
Mutis T, Lokhorst HM. Lenalidomide alone or in combina-
tion with dexamethasone is highly effective in patients with
relapsed multiple myeloma following allogeneic stem cell
transplantation and increases the frequency of CD41Foxp31
T cells. Leukemia. 2009;23:605-607.
305. Kaufman JL, Waller EK, Torre C, Boswell MG. Bortezomib
inhibits T cell proliferation. Blood. 2003;102:#3946.
306. SunK,Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of
acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc
Natl Acad Sci USA. 2004;101:8120-8125.
307. Shaughnessy PJ, Bolwell BJ, Abhyankar S, et al. A multi-
institutional study of extracorporeal photoimmune therapy
with UVADEX(R) for the prevention of acute GVHD in
patients undergoing standard myeloablative conditioning and
allogeneic hematopoietic stem cell transplantation. Blood
(ASH Annu Meet Abstr.). 2004;104:1230.
308. El-Cheikh J, Michallet M, Nagler A, et al. High response rate
and improved graft-versus-host disease following bortezomib
as salvage therapy after reduced intensity conditioning alloge-
neic stem cell transplantation for multiple myeloma.Haematol-
ogy. 2008;93:455-458.
309. Kroger N, Zabelina T, Ayuk F, et al. Bortezomib after dose-
reduced allogeneic stem cell transplantation for multiple mye-
loma to enhance or maintain remission status. Exp Hematol.
2006;34:770-775.
310. van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable
activity of novel agents bortezomib and thalidomide in patients
not responding to donor lymphocyte infusions following
nonmyeloablative allogeneic stem cell transplantation inmulti-
ple myeloma. Blood. 2006;107:3415-3416.
311. Byrne JL, Carter GI, Bienz N, Haynes AP, Russell NH.
Adjuvant alpha-interferon improves complete remission rates
following allogeneic transplantation for multiple myeloma.
Bone Marrow Transplant. 1998;22:639-643.
312. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma
idiotype-specific immunity from an actively immunised mar-
row donor. Lancet. 1995;345:1016-1020.
313. Neelapu SS, Munshi NC, Jagannath S, et al. Tumor antigen
immunization of sibling stem cell transplant donors in multiple
myeloma. Bone Marrow Transplant. 2005;36:315-323.
314. Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens
are commonly expressed in multiple myeloma and induce sys-
temic immunity following allogeneic stem cell transplantation.
Blood. 2007;109:1103-1112.
315. Szmania S, Gnjatic S, Tricot G, et al. Immunization with a re-
combinant MAGE-A3 protein after high-dose therapy for
myeloma. J Immunother. 2007;30:847-854.
316. Kroger N, Shaw B, Iacobelli S, et al. Comparison between
antithymocyte globulin and alemtuzumab and the possible im-
pact of KIR-ligand mismatch after dose-reduced conditioning
andunrelated stemcell transplantation in patientswithmultiple
myeloma. Br J Haematol. 2005;129:631-643.
317. Bellucci R, Alyea EP, Chiaretti S, et al. Graft-versus-tumor
response in patients with multiple myeloma is associated with
antibody response to BCMA, a plasma-cell membrane recep-
tor. Blood. 2005;105:3945-3950.
318. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy
of donor lymphocyte infusions given after reduced-intensity
conditioning allogeneic stem cell transplantation. Blood. 2002;
100:3108-3114.
319. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW,
Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma
effect of donor lymphocyte infusion in indolent lymphomas
relapsed after allogeneic stem cell transplantation.BoneMarrow
Transplant. 2003;32:1159-1163.
320. Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation
for Hodgkin lymphoma. Br J Haematol. 2008;143:468-480.
321. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-
leukemia activity may overcome therapeutic resistance of
chronic lymphocytic leukemia with unmutated immunoglobu-
lin variable heavy-chain gene status: implications of minimal
residual disease measurement with quantitative PCR. Blood.
2004;104:2600-2602.
322. Gribben JG. Salvage therapy for CLL and the role of stem cell
transplantation. Hematology Am Soc Hematol Educ Program.
2005;292-298.
